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 Zusammenfassung 
Arteriogenese bezeichnet das adaptive Wachstum von präexistenten kollateralen 
Arterien. Im Falle eines Arterienverschlusses ist Arteriogenese der endogen 
effizienteste Kompensationsmechanismus, um das Hypoperfusionsgebiet mit 
ausreichend Blut zu versorgen (Biologischer Bypasses). In dieser Arbeit wurde das 
frühe Wachstum von Kollateralgefäßen im Gehirn im ersten Modell für zerebrale 
Arteriogenese, dem 3-VO Modell (3-vessel occlusion), in der Ratte charakterisiert.  
(I)  Die Untersuchung am nicht-ischämischen 3-VO Hypoperfusionsmodell zeigten, 
dass 7 Tage nach 3-VO die Arteria cerebri posterior (PCA) signifikant im Diameter 
anwächst. Histologische Untersuchungen konnten ein vermehrtes Zellwachstum in der 
PCA und das Einwandern von Makrophagen in den perivaskulären Bereich (24 Stunden 
und 3 Tage post 3-VO) darstellen und eine Aktivierung des Endothels 3 Tage nach 3-
VO wurde mittels Rasterelektronenmikroskopie identifizieren. 
(II) Für eine genaue Anaylse des globalen Genexpressionsprofils der zerebralen 
Arteriogense wurde die wachsende PCA selektiv aus dem Gehirn entnommen und ein 
Genexpressionsprofil für die frühe zerebrale Arteriogenese erstellt (164 Gene 
dereguliert). Eine Unteruschung von biologischen und molekularen Prozessen zeigte, 
dass eine Vielzahl der deregulierten Gene in Zellproliferation und Inflammation 
involviert sind. Die Expression der Protease-Inhibitoren Kininogen und TIMP-1 wurde 
als “Marker” der frühen Arteriogenese in der PCA lokalisiert werden.  
(III) Eine funktionelle Relevanz der Kininogen-Bradykinin-Signalwirkung für die 
Arteriogenese wurde im Arteria Femoralis Ligatur Modell am Mäusehinterlauf 
untersucht und zeigte, dass sowohl in Bradykinin Rezeptor (BR1) knockout (KO), in 
BR2 KO, und in B1R/BR2 doppel-KO Mäusen die Arteriogenese signifikant reduziert 
ist.  
Zusammenfassend zeigt diese Arbeit erstmals eine Übersicht der biologischen Prozesse 
in der zerebralen Arteriogenese und eröffnet neue Ideen für eine mögliche 
therapeutische Strategie. 
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 Abstract  
Arteriogenesis, the adaptive outward growth of pre-existing collateral arteries, is the 
most efficient endogenous rescue mechanisms in vertebrates against the occlusion of a 
major artery (biological bypass). Here, collateral growth was induced using the first 
model for cerebral arteriogenesis, the 3-vessel occlusion (3-VO) rat model.  
(I) 3-VO resulted in a significant diameter increase within 7 days in the posterior 
cerebral artery (PCA) and posterior communicating artery (Pcom), classifying the 
region of interest. Immunhistological staining demonstrated proliferative activation and 
macrophage invasion, already 24h post 3-VO within the PCA, confirming the 
arteriogenic phenotype. Furthermore, activation of the PCA endothelium was detected 
within 3 days post 3-VO by scanning electron microscopy.  
(II) For analysing the molecular mechanism of cerebral arteriogenesis, collateral tissue 
from the growing PCA was selectively isolated. Here, 24h post 3-VO 164 genes were 
detected to be significantly deregulated. Analysis of molecular annotations and 
networks associated with differentially expressed genes revealed that expression 
patterns contain gene transcripts predominantly involved in proliferation, inflammation, 
and migration. Early-phase cerebral arteriogenesis is characterized by protease inhibitor 
expression and showed that protease inhibitors TIMP-1 and kininogen are molecular 
markers of early-phase cerebral arteriogenesis.   
(III) Functional relevance for kininogen-bradykinin signaling in arteriogenesis was 
analysed using the femoral artery ligation model in the mouse hind limb. 7 days post 
ligation arteriogenesis was significantly lower among B1-receptor (B1R) knockout 
(KO), B2R KO, and B1R/B2R double KO mice strains as compared to wild type 
animals. 
In summary, this work characterizes morphological features and genomic profiles of 
growing collaterals in the brain and develops novel ideas for a therapeutic stimulation of 
arteriogenesis. 
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Falls Gott die Welt geschaffen hat, war seine Hauptsorge sicher nicht, 
sie so zu machen, dass wir sie verstehen können. 
Albert Einstein
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1. Introduction 
The vascular system in mammals can been seen as one interconnected highly complex 
and organized organ system relevant for supplying oxygen and nutrients to all variants 
of tissue in the body (Risau, 1997). The function of the vascular system is of such 
importance that minor disorders can lead to severe disability and death. Cardiovascular 
disease is the leading cause of death in industrialized countries, among which stroke is 
the third most common cause of death and lasting disability. Still, therapeutic options 
are limited (Jones, et al., 2008; Lloyd-Jones, et al., 2009). Clinical studies have 
demonstrated the importance of an adequate hemodynamic compensation of cerebral 
blood flow to prevent brain ischemia in the context of atherosclerotic vascular diseases 
(Erdo and Buschmann, 2007). In order to develop a preventive concept against stroke, 
the understanding of the underlying vascular biology is of major concern.  
 
Different forms of physiological vascular remodelling can be distinguished, of which 
arteriogenesis in particular has high clinical relevance. It was shown that arteriogenesis 
is the endogenous most efficient mechanism to compensate for an artery occlusion or 
stenosis (Carmeliet and Jain, 2000). Arteriogenesis denotes a proliferation and growth 
of pre-existent collateral vessels, classical anastomoses located e.g. in the myocardium, 
the lower extremities and the brain (Longland, 1953). Collateral arteries can 
dramatically increase their lumen by growth, bypassing the site of occlusion of a major 
artery and preventing imminent ischemia (concept of the biological bypass).  
 
Experimental studies have provided evidence that growth of collateral arteries 
(arteriogenesis) can be enhanced therapeutically, which may reduce ischemic injury in 
endangered territories of the peripheral and cardiovascular system. In contrast to earlier 
descriptions of peripheral and myocardial arteriogenesis, corresponding results have 
long been missing for cerebral arteriogenesis. Recently, the three-vessel occlusion (3-
VO) model in the rat was introduced to analyse cerebral arteriogenesis, which induces a 
compensatory growth of collateral arteries in the brain (Busch, et al., 2003). By 
occluding three of four extracranial arteries to the brain, one carotid artery and both 
vertebral arteries (3-vessel occlusion), a significant redistribution of blood flow is 
induced via the posterior cerebral artery (PCA), which showed a significant positive 
outward remodelling, increasing its diameter by 38 %. In addition, application of the 
pro-inflammatory granulocyte-macrophage colony-stimulating-factor (GM-CSF) in the 
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latter, same hypoperfusion model led to a further therapeutic increase in collateral 
growth (Heil, et al., 2000; Hossmann and Buschmann, 2005) and correlated with a 
significant reduction in experimentally induced stroke volume (Schneeloch, et al., 
2004). This was the first evidence of therapeutic arteriogenesis in the brain (Love, 
2003). In order to find novel therapeutic pharmaceutical compounds to treat arterial 
occlusive disease, increasing efforts are undertaken to unravel the molecular processes 
of adaptive arteriogenesis (Lee, et al., 2004),(Prior, et al., 2003), (Buschmann, et al., 
2001). 
 
The purpose of this study was to induce collateral growth in the rat brain by employing 
the 3-VO model and to subsequently investigate the early phase of gene expression 
within the selectively isolated proliferating collateral pathways. Hence, this work is 
dedicated to (I) characterizing the 3-VO model, (II) analysing the molecular biology of 
the mechanisms which drive early-phase cerebral arteriogenesis, and (III) identifying 
novel key factors of arteriogenesis. To our knowledge, this is the first study which 
analyses the molecular mechanisms of arteriogenesis in the brain.   
The introduction briefly reviews the basic mechanisms of vascular remodelling in 
general (see section 1.1.) and will focus on the current knowledge about arteriogenesis 
(section 1.2.). Here, the introduction summarizes the morphological features of 
arteriogenesis (section 1.3.), and the methods and animal models in arteriogenesis 
research (section 1.4.). The introduction explains the 3-VO rat non-ischemic 
hypoperfusion model used in this study and shows its relevance for cerebral 
arteriogenesis research (section 1.5.). The genomic studies for arteriogenesis research 
are briefly summarized in section 1.6. Section 1.8 deals with the components and 
features of the kininogen system and bradykinin signaling, since molecular analysis of 
early-phase arteriogenesis highlight the prominent role of protease inhibitors, such as 
kininogen (part II). Functional relevance of kininogen-bradykinin signaling is shown in 
part III of this study. 
 
1.1. Vascular Remodelling 
The cardiovascular system plays a critical role in all vertebrates. Therefore, vascular 
development and maintenance consist of a highly organized series of events that 
requires the correct spatial and temporal expression of specific sets of genes. Three 
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different forms of vessel growth can be distinguished: vasculogenesis, angiogenesis, 
and arteriogenesis (Arras, et al., 1998; Buschmann and Schaper, 1999; Ito, et al., 1997). 
 
Vasculogenesis describes the initial events in the development of the embryonic 
vasculature and comprises the in situ differentiation of mesodermal stem cells, termed 
angioblasts, into capillaries. The cardiovascular system is the first functional organ 
system to develop in the vertebrate embryo. Vasculogenesis leads to the arrangement of 
the first major intra-embryonic blood vessels (Risau, 1997), such as the dorsal aorta, the 
cardinal veins, and to the formation of the primary vascular plexus in the yolk sac. The 
basic network is guided by the unique structural and molecular features available in the 
embryo and is determined by genetic programming. With the onset of blood flow, these 
primary vessels have to be remodelled into arteries in order to develop a functional 
vascular circle. Organization of vascular development is increasingly taken over by 
feedback signals derived from vascular functions including blood flow and ischemia, 
which are the initial signals for arteriogenesis and angiogenesis. As a general rule, 
remodelling of the primary vascular plexus into a more mature vascular system as well 
as postnatal adaptation of the vascular system are thought to occur by angiogenesis and 
arteriogenesis.  
 
Angiogenesis denominates the sprouting of endothelial cells leading to the development 
of capillary networks (Folkman, 2007) in normal physiological conditions (growth, 
exercise) and following cellular hypoxia as observed in pathologic conditions, such as 
systemic hypoxia, cancer, stroke, and other ischemic vascular disease. Pioneering work 
in the field of angiogenesis, especially with regard to the vascularization of tumors, has 
been performed by Folkman (Folkman, 1971). Tissue ischemia leads to the expression 
and activation of the transcription factor HIF-1. HIF-1 functions as a key regulator of 
oxygen homeostasis. Its expression leads to an increase of the transcription of several 
genes, including those encoding for NOS 1–3 and VEGF (Ryan, et al., 1998), 
(Carmeliet, 2005). In result, one of the first identifiable phenomena during tissue 
ischemia is vasodilation due to increased levels of NO and other not yet defined 
transmitters. Secondly, an increase in vascular leakage is observed due to the increased 
levels of VEGF (also known as vascular permeability factor). In fact, the occurrence of 
edema is a strong predictor of the angiogenic response. Apart from oedema, VEGF also 
induces, albeit moderately, endothelial cell proliferation. In summary, angiogenesis 
results in the de novo formation of capillaries in the hypoxic area, while the driving 
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force of angiogenesis is ischemia. Arteriogenesis, the main focus of this study, is, in 
contrast, independent of hypoxia and for ischemia. 
 
1.2. Arteriogenesis  
Arteriogenesis refers to a positive outward remodelling of pre-existing collateral arterial 
networks into larger calibre vessels which is a conserved mechanism in all vertebrates 
(Buschmann and Schaper, 1999). Collateral arteries are present in the newborn and 
adult organism. The presence of these pre-existent collateral connections was first 
reported in 1669 by Richard Lower at Oxford University. He observed very precisely 
the presence of pre-existent collateral connections between different vascular regions. 
Today, we know that pre-existent collateral arterioles are present in the peripheral, 
coronary, and cerebral circulation. Fulton et al. (Fulton, 1964) already recognized their 
function as alternative pathways for blood flow in case of flow deficiency, such as in 
case of an arterial disease.  
 
Figure 1. Principle of arteriogenesis  
(Modified, F.LeNoble) 
Arteriogenesis refers to the positive out-growth of collateral arterial networks following an arterial 
stenosis. Collateral arteries represent arteriolar anastomoses which interconnect different regions of major 
arteries. Therefore, in case of occlusion of a major artery, collateral arteries may function as a biological 
bypass which are capable of restoring blood flow to the ischemic area. In conclusion collateral artery 
growth determines clinical outcome. 
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An arterial disease is a condition that affects the arteries either by blocking or 
weakening blood vessels. Organs and other body structures may be damaged as a result 
of decreased or completely blocked blood flow (e.g. myocardial infarct or stroke), 
leading to a redistribution of flow to collaterals. Arteriogenesis constitutes an effective 
biological rescue mechanism against detrimental effects of arterial stenosis (Figure 1). 
In result, a small collateral artery grows into a bigger functional conductance artery, 
which circumvents sites of occlusion (Buschmann and Schaper, 2000): a biological 
bypass.  
 
Hence, arteriogenesis is of high clinical relevance. However, in many cases adaptive 
arteriogenesis still falls short of complete hemodynamic compensation, since the rate of 
increase in collateralization falls below the increase of stenotic vessel occlusion. It is 
now recognized that stimulating arteriogenesis constitutes a potentially novel 
therapeutic option as a preventive concept against cardiovascular diseases being 
evaluated in the context of atherosclerotic vascular diseases (Ito, et al., 1997; Kalka, et 
al., 1999). Unfortunately, research that deals with therapeutic induction of vascular 
remodelling often does not correctly differentiate the forms of vascular growth. Still, 
frequently studies deal with counting de novo formed capillaries (angiogenesis) in the 
ischemic region which is not the sufficient method to gain qualified information about 
the pro-arteriogenicity of curtain compounds (Banai, et al., 1994). Arteriogenesis shares 
some features with angiogenesis, but the pathways leading to it are different, as are the 
final results: arteriogenesis is potentially able to fully replace an occluded artery, 
whereas angiogenesis cannot. In contrast to sprouting angiogenesis in the ischemic 
region, arteriogenesis deals with vessels outside the ischemic region in oxygen-rich 
tissue where a collateral system surrounds the site of occlusion (Pipp, et al., 2003). 
Increasing the number of capillaries within the ischemic region cannot significantly 
increase blood flow when its limiting structure lies upstream. Furthermore, according to 
the law of Hagen-Poiseuille, perfusion ν is mainly determined by the vessel radius r to 
the power of 4. Thus, only minimal changes in vessel diameter of a pre-existent arteriol 
lead to a big difference of the perfusion level (arteriogenesis). All other factors like 
viscosity η, pressure differences ΔP, and distance differences (vessel length) Δl as well 
as flow volume V are still proportional according to the equation.  
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Figure 2. Law of Hagen -Posieuille 
(Modified, Klabunde, R.E) 
Equation clarifies the relationship between flow and vessel radius to the power of 4. Flow volume ν, 
viscosity η, pressure differences ΔP, distance differences (vessel length) Δl, radius r. 
 
The relationship between flow and vessel radius to the fourth power is illustrated in 
Figure 2, and shows how very small increases in radius dramatically enhance flow. 
In conclusion, newly formed small vessels cannot compensate for the loss of a main 
supplying arterial vessel (angiogenesis). This basic physiological principle has been 
shown in a number of clinical trials, where therapeutically induced angiogenesis has led 
to a significant increase in capillary density, but without significant beneficial effects on 
tissue perfusion (Storkebaum and Carmeliet, 2004; Wang, et al., 2005; Zadeh and Guha, 
2003). In contrast, adaptive proliferation of collateral vessels (arteriogenesis) represents 
the most important physiological protection mechanism against arterial stenosis 
(Carmeliet, 2000).  
 
For developing a potent therapeutic strategy to stimulate arteriogenesis, the genomic 
program and basic mechanisms of arteriogenesis need to be analysed. This will help to 
invent new medicinal therapies and lay the foundation for a strategy to therapeutically 
induce cerebral arteriogenesis as a preventive concept for stroke. 
 
1.3. The Mechanisms of Arteriogenesis 
Thoma et al (Thoma, 1893) found that vessels that carry a lot of blood flow enlarge, 
while those that carry little flow degenerate. Murray subsequently postulated that 
vessels adapt to flow in order to optimize the shear stress to which they are subjected 
(Murray, 1926). These studies have shown that flow can alter luminal dimensions of 
arterial segments. In fact, arteries are permanently exposed to hemodynamic forces 
because of the pulsatile nature of blood pressure and flow. Hence, the endothelium is 
constantly detecting different biomechanical forces, cyclic stretch and shear stress in 
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particular, and converts the latter stimuli into intra- and extracellular signals. Occlusion 
of a major artery leads to a significant increase in blood flow, resulting in high levels of 
shear. Shear force, not ischemia, plays the key role in adaptive phases of collateral 
artery growth, and was shown to be the driving force of arteriogenesis (Buschmann and 
Schaper, 2000; Hoefer, et al., 2004; Ito, et al., 1997). In fact, the overall impact of shear 
forces was shown by Schaper and colleagues, who induced an abrupt increase in shear 
stress by means of an arterial–venous (AV) shunt. An AV-shunt leads to a large and 
permanent pressure gradient (pressure drop across collateral arteries) and forces most of 
the collateral flow to empty into the vein. The result of shunting was a marked increase 
in collateral flow, which accelerated the speed of arteriogenesis (Eitenmuller, et al., 
2006) (Figure 3). 
 
 
Figure 3. Therapeutic stimulation of arteriogenesis  
(Modified, Eitenmüller, Circ Res. 2006)  
Angiography of the rabbit hindlimb 3 weeks post femoral artery ligation. Arteriogenesis can be 
stimulated by increasing fluid shear stress or by application of pro-inflammatory cytokines. A: before 
stimuation, B: following stimulation. White arrows indicate site of occlusion. Stars show collateral vessel 
area.  
 
Shear stress must be present for several hours before the endothelium becomes 
activated, which manifests itself in swelling of endothelial cells, proliferation, and 
edema (Schaper, 2004). Mechanoactivation of endothelial cells results in an 
upregulation of a number of genes which modulate multiple physiological processes: 
production of vasodilators (eNOS), growth factors (FGF) and cell adhesion proteins 
(ICAM, VCAM), mediation of inflammation by NF-kB, and expression of chemota-
attractants (MCP-1) (Hoefer, et al., 2004). 
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The secreted pro-inflammatory cytokines attract monocytes, which then adhere to 
endothelial cell adhesion molecules, transmigrate, and accumulate in the perivascular 
tissue of proliferating collateral arteries (Deindl, et al., 2001; Hoefer, et al., 2005). After 
infiltration, the monocytes mature to macrophages, producing again numerous cytokines 
such as FGF, MCP-1, and TNF-α and degrading enzymes (MMP-2, MMP-9), thereby 
creating the controlled inflammation necessary to remodel an arteriole into an artery 
(Schaper, et al., 1967). In result, extracellular matrix is degraded. The surrounding 
tissue, consisting of smooth muscle cells, endothelial cells, and fibroblasts is stimulated 
and starts to proliferate. Collateral arterioles develop into large collateral arteries via a 
positive outward remodelling (Fabricius, et al., 1996; Gupta, et al., 1999; Ma, et al., ; 
Schneeloch, et al., 2004). This scenario is largely similar to the processes occurring 
during tissue injury and other inflammatory processes, and the factors involved are 
often identical (Hoefer, et al., 2004; Joussen, et al., 2002). These findings and the 
observation that paracrine effects invading monocytes are a key feature of arteriogenesis 
constitute the basis for the recent clinical and experimental interest (Bergmann, et al., 
2006; Polverini, et al., 1977). 
Therapeutic stimulation of arteriogenesis is possible e.g. through the exogenous 
application of MCP-1, via administration of monocytes (Hoefer, et al., 2004; Park, et 
al., 2008), or GM-CSF (Love, 2003) by prolonged monocyte survival. Infusion of MCP-
1 and GM-CSF result in rapid enhancement of proliferation of pre-existing vessels after 
occlusion of a major coronary or peripheral artery and significant improvement of blood 
supply by stimulation of collateral growth (Arras, et al., 1998; Buschmann, et al., 2001; 
Ito, et al., 1997; Seiler, et al., 2001; Van Royen, et al., 2001). 
 
In conclusion, interplay between vascular and cellular reactions to hemodynamic and 
molecular signals regulates the induction of arteriogenesis. First, flow induces 
expression of genes in endothelial cells, and second, paracrine inflammatory process 
which correlate with monocyte invasion into the perivascular space (Schaper, 2004). 
It is well known that the architecture of arterioles and collateral growth differ slightly in 
the periphery and the heart. Arteriogenesis in the heart is initiated by monocyte 
invasion. These cells adhere initially to the endothelial surface and invade the intima. 
Later on the perivascular space becomes populated with monocytes, which supply space 
for the expanding collateral vessels by removing tissue that is in the way. In contrast 
neointima is not well developed in the vascular periphery, as it was shown  in the mouse 
hind leg. Here, only a few monocytes adhere to the shear-stressed endothelium, and 
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possibly leaky post-capillary venules may enable their marked invasion of the 
perivascular space (Cai and Schaper, 2008). 
 
These basic principles of arteriogenesis, as shown above, reflect our current knowledge 
in collateral artery biology and could repeatedly be confirmed in several in vivo studies 
for coronary and peripheral arteriogenesis. Yet, it is completely unknown what governs 
cerebral arteriogenesis due to the lack of an appropriate animal model in the brain.  
 
1.4. Animal models in arteriogenesis research 
Stimulation of collateral artery growth (arteriogenesis) provides a potential alternative 
option for the treatment of patients suffering from occlusive artery disease. Therefore, 
researchers have established several animal models to investigate basic mechanisms and 
pharmacological modulation of collateral artery growth: a coronary model (dog (Wolf, 
et al., 1998)) and several peripheral models (mouse (Scholz, et al., 2002)), in rat 
(Herzog, et al., 2002), rabbit (Ito, et al., 1997), or pig (Pipp, et al., 2004).  
The choice of the correct animal model is important concerning the outcome, the 
specificity for one of the vascular remodelling processes (arteriogenesis, angiogenesis, 
vasculogenesis), and finally the clinical relevance. For an arteriogenesis model it is 
relevant to have an occlusion of a major artery resulting in hypoperfusion of the distal 
region, however, without forming a region of absolute ischemia, leading to severe tissue 
necrosis (development of an infarct areal) (Deindl and Schaper, 2005).  
 
Certain physiological and morphological features have to be evaluated within each 
model in order to study arteriogenesis. First, an important tool in evaluating 
arteriogenesis is the measurement of perfusion by laser-Doppler technique (LDF) to 
determine collateral perfusion under different conditions, which is particularly used in 
small-animal species such as mice and rats (Heil, et al., 2002; Silvestre, et al., 2002). 
LDF assesses blood flow by detecting the flow velocity of corpuscular blood 
components (erythrocytes) through the reflected laser beam.  
Second, growing collateral have to be identified and characterized. Histological staining 
for proliferation markers (PCNA and Ki-67) allows identification of collateral arteries 
in which an examination of the diameter or lumen area after maximal vasodilation can 
be performed. Furthermore, staining for the macrophage marker CD68 shows 
macrophage invasion, a common feature of arteriogenesis as described above. 
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Comparing vascular proliferation and macrophage invasion at different time points, 
however, gives strong hints of the outcome of the arteriogenic process.  
 
Currently there are a number of efforts underway to develop new in vitro systems as 
alternative methods to analyse the basic mechanisms of arteriogenesis in artificial 
arteries. In vitro models are frequently used to understand flow dependent activation of 
endothelial cells under simulated flow conditions which help to understand the 
processes of collateral growth. However, this approach is still not sufficient to mimic 
the in vivo situation and analyse the basic mechanism of collateral growth, which still 
need to be performed in well-characterized arteriogenesis animal models. 
 
Thanks to the rising use of transgenic and knockout models, increasing efforts are made 
to transfer the study of arteriogenesis into the mouse. Since the introduction of 
transgenic mouse strains into experimental research, their accessibility has helped to 
improve our understanding of the biological mechanisms of vascular growth. Therefore, 
the mouse model would provide a powerful tool to further illuminate basic mechanisms 
of arteriogenesis. This is especially important for the functional analysis of novel 
candidate genes for clinical relevance in transgenic animal models (Pipp, et al., 2003) 
(Scholz, et al., 2003; van Royen, et al., 2003). 
 
In this study, morphological and transcriptional patterns for cerebral arteriogenesis were 
analysed in the rat brain 3-VO model (1.5.). Consequently, the mouse hind limb model 
of femoral artery occlusion was used to analyse the functional relevance of kinin 
signaling for arteriogenesis in bradykinin receptor KO mice (1.6.).  
 
1.5. The 3-VO model of cerebral arteriogenesis 
Analyzing collateral arteries in the brain is challenging due to the anatomical 
conditions. However, a multitude of extra- and intracranial collateral systems, such as 
the leptomeningeal anastomoses of Heubner, the anastomotic pathways via the 
ophthalmic artery, or the circle of Willis provide the chance of improving blood supply 
under conditions of slowly progressing vascular occlusion (Hossmann, 1993). Here, the 
circle of Willis, named after the English anatomist Thomas Willis, is of particular 
interest (Figure 4). It comprises the anterior, medial and posterior cerebral arteries 
(ACA, MCA, PCA), and the anastomoses, which connect them. The brain is supplied 
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by blood through four arteries: two vertebral arteries and two carotid arteries (Delank, 
2006; Poeck, 2006), which all feed into the cerebral circulation via the circle of Willis.  
 
Recently, the three vessel occlusion model (3-VO) model was established by Busch et 
al. in rat, for the first time allowing the investigation of cerebral arteriogenesis under 
controlled conditions (Busch, et al., 2003). Due to the small size of a mouse, the 3-VO 
model is yet only technically applicable in rats, since a controlled paravetebral 
occlusion of the vertebral arteries in mice is not feasible. Furthermore, the morphology 
of the cerebral arteries is very similar between humans and rats, including anomalies 
and structure of these vessels as well as their morphologic changes associated with 
cerebral vascular disease (Lee, 1995) (Figure 4). 
 
3-VO describes a bilateral occlusion of the vertebral arteries in combination with 
unilateral carotid artery occlusion, which leads to cerebral hypoperfusion. The perfusion 
via the open right carotid artery accounts for an efficient cerebral perfusion, preventing 
neurological deficits.  
 
Figure 4. Circle of Willis. 3-vessel occlusion model in the rat brain.  
A: Circle of Willis in man (Modified, Lee 2005), B: Circle of Willis in rat (Paxinos, 2004). Red barrs 
indicate occlusion of three vessels, one carotid, both vertebral arteries. Red arrows indicate redistribution 
of blood flow following 3-VO surgery. Post 3-VO blood may circulate into the brain via the carotid artery 
contralateral of the occlusion (left side) and is redistributed via the PCA and ACA region to the ipsilateral 
brain region (right side).  
The circle of Willis 
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By occluding three of four extracranial arteries to the brain, a significant redistribution 
of blood flow is induced via the posterior cerebral artery (PCA) (Figure 4), which 
shows a significant positive outward remodelling, increasing its diameter by 37 % 
within 7 days (Hillmeister, et al., 2008). 
 
Morphological studies show that shortly after occlusion a lasting reduction in 
cerebrovascular reactivity (CVR) occurs, but without histomorphologically detectable 
localized ischemic-necrotic tissue damage (Busch, et al., 2003). The animals do not 
show neurological deficits. For the first time a cerebral arteriogenesis model was 
designed, which allows the study of collateral growth in the brain under controlled 
conditions.  
Furthermore, Buschmann et al. could show that the arteriogenesis in the 3-VO model is 
therapeutically inducible by the application of the pro-inflammatory cytokine 
granulocyte-macrophage colony stimulating factor (GM-CSF). In the same 
hypoperfusion model, application of GM-CSF led to a further therapeutic increase in 
collateral growth (Buschmann, et al., 2003; Hossmann and Buschmann, 2005),and 
correlated with a significant reduction in experimentally induced stroke volume 
(Schneeloch, et al., 2004). This was the first evidence for inducible therapeutic 
arteriogenesis in the brain (Love, 2003). 
These results provide the basis for the planned studies of a new strategy of stroke 
prevention as well as the treatment of acute cerebrovascular insufficiency by therapeutic 
stimulation of arteriogenesis (Love, 2003). However, since treatment with GM-CSF is 
associated with a number of unspecific side effects, the logical consequence of the 
results at hand is to strive for a more detailed insight into molecular mechanisms to 
identify more specific therapeutic targets. Therefore, gene expression profiling studies 
shall give a direction.  
 
This study aims at a comprehensive understanding of the genomic program activated 
during early-phase collateral vessel growth in a rat model of cerebral adaptive 
arteriogenesis (3-VO).  
 
Introduction                                                                                                                          13 
  
 
1.6. The Femoral artery occlusion model in mouse 
Ligation of the femoral artery in the hind limb, leaving all branches intact and 
functional, is the prototype of a pure arteriogenesis model, because it does not lead to 
ischemia and hypoxia at the site of vessel growth (Hoefer, et al., 2006).  
 
Figure 5. Femoral artery oclusion model (Modified, Lee, JACC 2004) 
Schematic illustration of the femoral artery occlusion procedure performed in the mouse hind limb. In this 
arteriogenesis model femoral artery ligation is performed twice: distal  to the inguinal ligament and 
proximal to the popliteral bifurcation.. Redistribution of blood flow results in collateral growth within the 
adductor muscle. 
 
Arteriogenesis was studied first in rabbit (Deindl, et al., 2001). Rabbits display a rapid 
arteriogenic response and make for a highly successful model, regarding size and cost-
efficiency. The femoral artery ligation model in the rabbit helped unraveling many 
processes of arteriogenesis in the periphery that can be stimulated (Figure 3) and 
inhibited, offering insights into mechanisms and potential therapeutic targets (Ito, et al., 
1997). Because of the success of the femoral artery ligation model for inducing 
arteriogenesis, this model was also established in other rodent models, mouse and rat, as 
well as in pig (Voskuil, et al., 2003).  
  
The femoral artery occlusion model in the mouse hind limb helps to directly compare 
quantitative data obtained from the use of transgenic animals or application of 
pharmacological inhibitors or stimulators of arteriogenesis. Therefore, studies dealing 
with arteriogenesis in different settings frequently analyse collateral growth in the 
femoral artery ligation model in mice.  Quantification of collateral growth is performed 
by measuring the collateral conductance by microsphere perfusion. Collateral 
conductance directly describes arteriogenesis under situations of maximal vasodilation. 
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Conductance is the reciprocal value of the vascular resistance and describes increase in 
blood flow per increase in pressure. 
 
 
Figure 6. Collateral Conductance 
Collateral conductance is the reciprocal value of the vessel resitance. In situations of maximal 
vasodilation, controlled pressure determines blood flow in the collateral region.  
 
Assessment of collateral-dependent flow using microsphere perfusion measurements 
remains the most precise experimental technique to quantify collateral growth and 
constitutes the gold standard in evaluating arteriogenesis (Schaper, 2004). However, the 
main disadvantages of this method are the direct and indirect costs, the necessity of 
taking tissue specimens for the quantification, and calculation of blood flow. 
Furthermore, collateral conductance in mice can be measured only by approximation, 
since ascertaining peripheral blood pressure is not feasible in mice. Still microsphere 
perfusion gives a capacity for collateral growth in mice which serves well to quantify 
arteriogenesis. 
 
1.7. Molecular mechanisms 
Whereas basic processes of arteriogenesis are understood, in which biomechanical 
endothelial activation and consecutive accumulations of monocytic cells are key initial 
events (section 1.3), the molecular mechanisms regulating this process are less defined. 
The development of collateral vessels is a tightly regulated and complex process 
requiring the action of multiple genes expressed in an appropriate time-dependent 
manner. In particular, it is important to know which genes are activated in the early-
time processes of collateral growth in order to understand what the molecular 
mechanism initiating arteriogenesis is. Profiting from the general progress in molecular 
and cellular biology and the recent advances in microarray technology, the tools to 
perform comprehensive, quantitative comparisons at the transcriptional level of 
thousands of genes simultaneously are provided (King and Sinha, 2001), which help to 
make the mechanisms of arteriogenesis much clearer. The only relevant great scale 
genomic analysis so far was performed by a pioneer work of Lee et al. (Lee, et al., 
2004), who studied collateral growth after femoral artery ligation in mice analysing 
12.000 genes for differential expression using affymetrix microarrays. Herein he found 
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783 genes as deregulated and identified an early induction, mid-phase induction and 
late-phase induction of collateral growth. 
 
In vitro studies identified genes expressed upon flow driven endothelial cell activation, 
such as KLF2 (Krüppel-like factor 2) (Dekker, et al., 2002), a VEGFR/PECAM 
complex (Tzima, et al., 2005), and  the calcium channel TRPV4 (Taniguchi, et al., 
2007; Vriens, et al., 2004). Furthermore, Schaper and collegues analysed gene 
expression in rapidly growing vessels in the rat hind limb by genome wide screening of 
transcripts using microarrays. Among the over 300 differentially expressed genes 
analysed, he found several of the known stress-responsive genes differentially 
expressed. 
Similar studies for cerebral arteriogenesis were not performed. This is in particular 
significant, since Faber and colleagues documented for the first time that collateral 
density and vascular remodelling in the brain differ widely between mouse strains 
(Chalothorn, et al., 2007). For their study they analysed the leptomeningeal anastomoses 
of Heubner on the dorsal part of the brain, discovering significant differences in 
collateralization for BALB/c (lowest collateralization) and C57BL/6 (highest 
collateralization) mice strains. This indicates that collateralization is influenced by, as 
yet unknown, genetic factors. Here, first functional studies reveal that genes of chloride 
intracellular channel-4 (CLIC4) and VEGF-A (Chalothorn, et al., 2007; Clayton, et al., 
2008) are determinant of native collateral formation in brain (Chalothorn, et al., 2009). 
Faber and colleges transferred their findings from collateral research of the brain to the 
mouse hind limb as well. As mentioned in section 1.6., arteriogenesis can be measured 
precisely in the femoral artery occlusion model and functional data can be compared to 
other studies. Thus, they found that collateralization in the skeletal muscle confirms the 
differences observed in the brain between mice strains (BALB/c and C57BL/6) 
(Helisch, et al., 2006), approving the relevance of CLIC4 and VEGF-A for 
arteriogenesis.  
 
Different genetical factors determinate differences in collateral remodelling, which 
result in large differences in flow impairment after arterial occlusion. Thus, the density 
and diameter of native (pre-existing) collaterals in healthy tissues and their capacity to 
remodel in ischemia are major determinants of the severity of tissue injury in 
obstructive vascular disease (Helisch and Schaper, 2003; Schaper, 2009; Sherman, et 
al., 2006). Evidence suggests that native collateral conductance varies widely in healthy 
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individuals (Meier, et al., 2007; Wustmann, et al., 2003). Understanding the genomic 
program of early-phase cerebral arteriogenesis leading to collateral formation is of 
fundamental importance to develop a potential strategy to induce cerebral arteriogenesis 
therapeutically as a preventive concept for stroke.   
 
1.8. The kininogen-bradykinin system  
Molecular analysis identified kininogen as a molecular marker of arteriogenesis. This 
work is dedicated to analysing the functional role of the novel identified target genes, 
such as kininogen for arteriogenesis. Therefore, the kininogen-bradykinin system is 
briefly summarized. 
 
Kininogen is cleaved by kallikrein which releases the nonapeptide bradykinin (Arg- Pro 
- Pro - Gly - Phe - Ser - Pro - Phe - Arg) and related kinins. The kinin system is a 
complex signaling network, that beside the precursor kininogens, consists of the 
proteolytic kallikrein enzymes, the Kinin peptides, and two G-protein-coupled receptors 
(GPCRs) termed the bradykinin receptor B1 and bradykinin receptors B2 (B1 and B2 
receptor) that mediate the biological effects of kinin peptides (Figure 7) (Emanueli and 
Madeddu, 2001; Madeddu, et al., 2007).  
There are two relevant kallikreins, which are encoded by distinct genes and differ in 
molecular weight, isoelectric point, amino acid sequence, immunogenicity, and 
susceptibility to inhibitors (Bhoola, et al., 1992). Tissue kallikrein is present in many 
tissues and various body fluids (Chao, et al., 2006; Chao, et al., 2001), whereas plasma 
kallikrein is almost exclusively found in circulating blood and is involved in the 
cascades of blood coagulation (Movat, 1979; Sainz, et al., 2007).   
Furthermore, kallikrein was reported to increase MMP activity, which governs the 
homeostasis of extracellular matrix degradation for vascular remodelling (Figure 7) 
(Regoli and Barabe, 1980). 
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Figure 7. The kinin system in the vascular wall  
(Modified, Stone, O 2009) 
Kininogen (KNG) is processed by Kallikrein (KLK1) to cleave bradykinin and kallidin. Kinins signal via 
the constitutively expressed B2 receptor and the inducible B1 receptor. Stimulation of the B2 receptors on 
endothelial cells (EC) activates the Akt-eNOS/GSK3 pathways, which results in EC proliferation. 
Stimulation of the B1 receptor on ECs and leucocytes induce mono-(MNC) and poly- (PMNC) 
morphonuclear cells transmigration into the perivascular space. These processes induce expression of 
further kinins and growth factors (GF). B2 receptor signaling in vascular smooth muscle cells (VSMC) 
and pericytes enhances NO dependent vasodilation. Moreover, KLK 1 may increase MMP activity that 
may lead to breakdown of the extracellular matrix (ECM). 
 
A single human kininogen gene encodes the production of two kininogen variants 
through alternative splicing: high-molecular-mass kininogen (HK; 88–120 kDa) and 
low-molecular-mass kininogen (LK; 50–68 kDa) (Chao, et al., 2006). Different 
kallikreins process the substrate kininogen, which liberates bradykinin and kallidin (also 
termed Lys-bradykinin). Bradykinin acts via the constitutively expressed bradykinin 
receptor 2 and kallidin via the inducible bradykinin receptor 1 (Regoli and Barabe, 
1980). The kinin peptides are implicated in a wide range of biological phenomena, 
including pain, inflammation, vasodilation, increased vascular permeability, and 
natriuresis (Bader, 2009; Regoli and Barabe, 1980). Furthermore, the kinin system is 
reported to counteract the well-characterized renin-angiontensin system and vice versa. 
Both systems are the most important signaling pathways regulating vascular biology. 
Kinins are local hormones (autacoids), which are highly vasoactive compounds. Several 
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reports have demonstrated the presence of a kinin system in the vascular wall (Stewen, 
et al., 2004). 
 
Kinins bind to the B1 and B2 receptor, which are found both on cultured smooth muscle 
cells as well as on endothelial cells (Figure 7). By signaling via the B2 receptor, 
bradykinin induces smooth muscle cell relaxation and vasodilation. Bradykinin 
signaling via the constitutively expressed B2 receptor on endothelial cells, results in EC 
proliferation, enhanced vascular permeability, and sprouting angiogenesis (Krankel and 
Madeddu, 2009). Stimulation of the B1 receptor leads to production of cytokines 
contributing to angiogenesis by paracine effects (Meneton, et al., 2001). Herein kinins 
share important features with VEGF (Ahluwalia and Perretti, 1999; Bhoola, et al., 
1992). Mechanistically, kinin signaling is known to activate the Akt-eNOS/GSK3Beta 
pathway, increasing nitric oxide levels, and reducing reactive oxygen species formation 
(Yao, et al., 2008).  Yet, a role for the kinin-system in arteriogenesis has not been 
described, which is remarkable since local increases in kinin level may attract mono- 
and polymorphonuclear cells, which themselves produce other growth factors - a major 
feature of arteriogenesis (Figure 7).  
 
Pathophysiological models have shown a clinical relevance for the kinin system. It was 
shown that activation of kinin signaling protects against ischemic stroke and myocardial 
infarction (Xia, et al., 2006). Brown-Norway Katholiek rats, which lack secreted 
kininogen, showed a reduced capacity for new vessel formation (Ikeda, et al., 2004). 
Reduced angiogenesis was also observed by blocking the B1 and B2 receptor. Knockout 
mouse strains have been produced for each receptor type and have confirmed their 
predicted roles (Emanueli, et al., 2002; Meneton, et al., 2001). Homozygous mutated 
animals lacking the B1 gene or the B2 gene were shown to be viable and to present 
normal development (Pesquero and Bader, 1998). Hence, bradykinin receptor KO mice 
were used in this study to analyse the role of bradykinin signaling for collateral growth. 
Furthermore, for the first time the role of a double knock out mouse strain B1/B2 
receptor was analysed in the context of vascular remodelling.  
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1.9. Research aims and objectives  
Purpose of this study was to demonstrating how therapeutic strategies for stimulating 
arteriogenesis can be developed out of a comprehensive gene expression analysis. 
Therefore, this work aimed at three objectives: (I.) to characterize the 3-VO brain 
arteriogenesis model to analyse morphological features of cerebral collateral growth. 
(II.) In particular, this study aims at understanding the molecular mechanisms and 
transcription profile of early-phase arteriogenesis; to identify novel target genes, which 
govern collateral development in the brain. (III.) This study aimed at showing the 
functional relevance of a newly discovered molecular marker of the genomic profile of 
arteriogenesis (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Flow chart of the study design 
This work aimed at identifying, out of a comprehensive gene expression anlysis of early-phase cerebral 
collateral growth, candidate genes in order to develop noval concepts. Therefore this work is structured in 
three parts. The first part aimed at characterizing morphological features of early-phase cerebral 
arteriogenesis and identifying the area of interest for molecular analysis. Part two aimed at performing a 
global genom analysis to understand the molecular patterns of early-phase cerebral arteriogenesis. 
Candidate genes should be further analysed by biomolecular methods. Finally part three shall answer the 
question whether the newly identified target gene has functional relevance for arteriogenesis. 
 
 
 
Establishment of 3-VO surgery for inducing  arteriogenesis in 
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the AOI by immunhistochemistry
Morphological analyis of ear ly-phase arteriogenesis in 
the AOI b y scann ing electron microscopy
II. Selective isolation of growing collaterals (AOI) of the brain for RNA extraction
Affymetrix chip hybr idisation exper iments
Significant analysis of microarrays (SAM) Ingenuity Analysis 
Analysisanalysis
Bioinformatics and genomic profiling
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III.
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(I.) Cerebral arteriogenesis was characterized in the 3-VO model by blood flow and 
vessel diameter measurements. Here, a growing collateral artery (PCA) was identified 
as area of interest. Morphological features of the area of interest was analysed by 
approved methods of arteriogenesis research (immunhistochemical analysis), as well as 
newly established methods (electron microscopy of vessel intima). 
(II.) To perform a comprehensive gene expression analysis tissue of the growing 
collateral was selectively isolated out of the rat brain, RNA extracted, and microarray 
hybridisation experiments were performed using the Affymetrix gene chip technology. 
Here, gene expression was analysed during early-phase of cerebral arteriogenesis to 
identify target genes, which may initiate arteriogenesis. Therefore, deregulated genes 
were clustered and annotated by several bioinformatics data bases (SAM, Igenuity, 
DAVID). Promoter regions of interesting target genes were scanned for regulatory 
elements, such as NF-kB binding sites and SSREs, and candidate genes (protease 
inhibitors). Protease inhibitors were identified as candidate genes and validated by qRT-
PCR and mRNA expression localized by in situ hybridisation.   
III. This study identified the protease inhibitor kininogen as target gene in early-phase 
cerebral arteriogenesis. For the purpose of vivo verification of data obtained in the 
molecular analysis, functional relevance of kininogen-bradykinin, signaling for 
arteriogenesis, was analysed using bradykinin receptor 1, bradykinin receptor 2, and 
bradykinin receptor 1/2 double KO mice. 3-VO model is yet not applicable to mice, for 
technical reasons (section 1.5.). Therefore, the technically available femoral artery 
occlusion model was used to assess the role of bradykinin signaling for arteriogenesis. 
This model is regularly used for the verification of data obtained in arteriogenesis 
research and allows precise assessment of arteriogenesis by measuring the collateral 
conductance. 
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2. Materials and Methods 
 
2.1. Animal model  
To analyze the morphological and molecular features of early-phase cerebral 
arteriogenesis, the 3-VO model in rat was used. Occlusion of the left carotid artery (CA) 
and both vertebral arteries was carried out as previously described in detail (Busch, et 
al., 2003) and is described in section 2.1.1. For analysing the functional relevance of the 
kinin-system using Bradykinin receptor KO mice, the femoral artery ligation model was 
used, since the 3-VO model is yet not applicable in mice. Furthermore, arteriogenesis 
was assessed in the hind limb by microsphere perfusion, which is the gold standard for 
measuring collateral growth. The femoral artery ligation model is described in section 
2.1.2.   
  
2.1.1. 3-VO surgery  
The non-ischemic brain hypoperfusion 3-vessel occlusion model (3-VO) was used to 
induce adaptive arteriogenesis in the brain without detectable neurological damage 
(immunohistological evaluation), as described by described in detail by Busch et al. and 
Schneeloch et al (Busch, et al., 2003; Schneeloch, et al., 2004). Experiments were 
carried out in male Sprague-Dawley rats (300-350 g, Harlan-Winkelmann, Borchen, 
Germany) in accordance with the German Law for the Protection of Animals and the 
National Institute of Health Guidelines for Care and Use of Laboratory Animals 
(license for animal testing G 0360/05). Animals were housed under diurnal lighting 
conditions and allowed access to food and water ad libitum. Anesthesia was induced by 
inhalation of 2 % to 4 % isoflurane and maintained with 2 % isoflurane in oxygen. 
Analgesia was achieved by Buprenorphine s.c., 0.1 mg/kg intraoperatively, and 0.05 
mg/kg s.c. BID for 2d after surgery. Vascular occlusions were carried out by 
electrocoagulation of both vertebral arteries, using a paravertebral access (Pulsinelli, et 
al., 1983), followed by left common carotid artery ligation. Successful 3-VO surgery 
was measured by laser Doppler flowmetry. At the end of experiments, animals were 
sacrificed, and the vessels of the circle of Willis were taken for RNA extraction or 
perfused with either ink-stained 37°C warm latex (via the left CA) for visualization of 
the cerebrovascular anatomy or with 4 % paraformaldehyde / PBS (via the left 
ventricle) for histological evaluation.  
 
Material and Methods                                                                                                        22 
  
 
 
2.1.2. Laser Doppler flowmetry 
To ensure cerebral hypoperfusion, CBF (Cerebral blood flow) was measured by 
transcranial laser Doppler flowmetry (LDF, PeriSoft, PeriMed, Järfälla, Sweden). 
Continuous laser Doppler flowmetry of both hemispheres was performed throughout the 
whole experiment. The skull above the frontoparietal cortex was exposed, and a laser 
probe was placed directly onto the skull bone. The LDF device was kept in an identical 
position before and after 3-VO. Changes of laser Doppler flow values are expressed as 
percentage of mean baseline values.  
 
2.1.3. Visualization of cerebral angioarchitecture  
Cerebrovascular anatomy was studied after maximal vasodilation by a modification of 
the postmortem latex perfusion method of Maeda et al (Maeda, et al., 1998). External 
PCA diameter was measured with a stereozoom microscope (Leica MZ6) equipped with 
a calibrated eyepiece micrometer. Data sets are presented as mean ± standard error of 
the mean. Diameter changes were analyzed for statistical significance by an unpaired 
Student’s t-test. Statistical significance was assumed for P < 0.05. 
 
2.2. Femoral artery ligation 
Bradykinin receptor 1 KO (n=10), bradykinin receptor 2 KO (Jackson Laboratory, Bar 
Harbor, Maine) (n=10), Bradykinin receptor 1+2 dobble KO mice (n=10), and wild type 
mice (n=10) underwent unilateral femoral artery ligation. (Licence for animal testing 
TVV G 0108/08). All mice were male and between 12 and 14 weeks of age and had a 
C57BL/6 background. The right femoral artery was ligated immediately distal to the 
inguinal ligament. Because collateral arteries develop from preexisting arteriolar 
connections spanning from the profunda femoris and circumflexa femoris to the 
genualis and saphena parva arteries, the femoral artery was not excised to leave these 
vessels intact. Wounds were closed and animals recovered. After the surgical procedure, 
the animals were housed in groups of 5 with free access to water and chow and were 
allowed to move freely. There were no signs of any gross impairment or necrosis.  
 
2.2.1. Collateral Conductance measurement 
Seven days after ligation, mice were anesthetized for microsphere-based flow 
calculations. To ensure perfusion of both hind limbs and optimal distribution of the 
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fluorescent microspheres, the abdominal aorta was cannulated with a polyethylene 
catheter (inner diameter, 0.58 mm; outer diameter, 0.96 mm). After stabilization of 
systemic pressure, both legs were perfused at 4 different pressure levels (70, 80, 90, and 
100 mm Hg, respectively) with saline and adenosine (1.0 mg/kg per min, Sigma) to 
achieve maximal vasodilation. At each pressure level, microspheres with a different 
fluorescent dye (red, blue-green, orange, or yellow-green; diameter, 15 _m; Molecular 
Probes) were thoroughly mixed and injected into the perfusion system. The hind limb 
muscles were dissected from the leg, weighed, homogenized, and digested with 
SDS/proteinase solution for FACS analysis and microsphere counting. 
 
2.2.2. Microsphere counts 
The following muscles were dissected from the leg: quadriceps, adductor longus, 
adductor magnus, gastrocnemius, soleus, plantaris and peroneal muscles. Each muscle 
was divided into three consecutive samples (0.5g) from the proximal to the distal end. 
Each muscle sample was weighted and samples were then homogenized and placed 
loosely in 15ml tubes (Becton Dickinson, Lincoln Park, NJ). To each of the tissue 
samples, the following was added: 3 ml of a proteinase/SDS solution [SDS stock 
solution: 1% SDS, 0.5 % sodium azide (both Sigma Chemical Company, St. Louis, 
MO) and 0.8 % Tween-80 (Fisher Scientific, Fair lawn, NJ) in 50 mM pH 8 Tris buffer 
(Sigma Chemical Company, St. Louis, MO)] and 1 mg/ml proteinase K (Boehringer 
Mannheim Corp.). Blue microspheres (4000/ml, diameter: 15 mm; Molecular Probes, 
Eugene, Oregon, USA) were used as an internal standard. Each tube was capped and 
secured in a shaking water bath at 50°C for 24 h. All samples were then centrifuged at 
1000g for 30 min; the supernatant was pipetted off and the pellet was resuspended in 1 
ml CellWash (Becton Dickinson, Lincoln Park, NJ). Directly before FACS analysis, the 
probes were rigorously shaken. For microsphere counting, a flow-cytometer 
(FACSCalibur) equipped with a second laser and a detector for a fourth fluorescence 
was used. After FACS analysis, each single microsphere was classified and counted 
with a computerized analysis system (Becton Dickinson, Lincoln Park, NJ). Hind limb 
collateralization was estimated by normalizing the number of microspheres in the 
sample with microspheres of a reference samples. The unligated left hind limb was 
processed in the same manner, as described above, defined as 100 % and served as the 
internal validation. Values generated represent a value for the perfusion reserve of the 
hind limb, which estimates collateralization and arteriogenesis. Data sets are presented 
as mean ± standard error of the mean. Diameter changes were analyzed for statistical 
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significance by a Bonferroni t-test. Statistical significance was assumed for P < 0.05, 
and  <0.01. 
 
2.3. Histological analysis 
For immunhistochemical analysis of the morphological features of cerebral 
arteriogenesis rats were submitted to occlusion of the left carotid artery (CA) and both 
vertebral arteries (3-VO) and enrolled into the study as follows: Control group (n=6); 
24h post 3-VO (n=6); 24h post sham (n=6); 3d post 3-VO (n=6); 3d post sham (n=6). 
Information regarding the used antibodies is provided in Table 4 section 2.8.2. Images 
were obtained using a Leica DM-R Microscope. 
 
2.3.1. Embedding, fixation and pretreatment of paraffin-embedded sections 
Brain tissue was cut into sagittal or coronal parts and submerged in fixative (0.01M 
PBS; 4 % paraformaldehyde) for 16 h at 4 °C overnight and subsequently washed in 
PBS at room temperature. Fixed tissues were dehydrated and paraffinized (Paraffin 9) in 
an embedding machine (Shanon Citadel 1000, Thermo). The embedding program 
included the following steps: 70 % ethanol for 1h, 96% ethanol for 1h, 100% ethanol for 
three changes (1h each), acetone for 30min, and paraffin wax for three changes (2x 1 h 
and 1x over night). Tissues were then embedded into paraffin blocks and cut on a 
microtome (Microm) in 5 μm sections, mounted onto slides, dried for 30 min and 
incubated at 60 °C for 1h. Paraffin sections were de-paraffinized for 5 min each in 
xylene (3 changes), 100 % ethanol, 96 % ethanol, 80 % ethanol, 70 % ethanol, and 
water.  
 
2.3.2. Immunoflourescence detection 
For epitope retrieval slides were boild in citrate buffer (10mM, Tween 20, pH 6.0) for 
20 min in a microwave, cooled down to room temperature for 40 min, rinsed in dH2O, 
and stored in PBS. The slides were rinsed in washing buffer (PBS, 0.05 % Tween 20, 
pH 7.2) and blocked with serum blocking solution (1 % serum, 1 % BSA, 0.1 % Triton 
X-100, 0.05 % Tween 20) for 30 min at room temperature. The used serum was derived 
from the same species as the secondary antibody (usually goat). 
Then, the sections were covered with the primary antibody diluted in PBS including 1% 
BSA for 1 hour at room temperature, and rinsed three times for 2 min in PBS. The 
sections were incubated with fluorescently labeled secondary antibodies (Cy3) diluted 
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1:200 in PBS for 30 minutes at room temperature and rinsed three times for 2 min in 
washing buffer. Cell nuclei were stained using Hoechst 33342 (1:1000 PBS, Molecular 
Probes Inc., Eugene, Oregon, USA). Slides were coverslipped with Flouromount-G 
(Southern Biotech). Twelve sections of each animal were analysed in a blinded 
approach by three independent investigators. 
 
2.3.3. Immunoenzyme (HRP) method 
Epitope retrieval, washing and blocking was performed as described above. 
Endogenous peroxidase activity was blocked by incubating paraffin sections in 3% 
H2O2 in PBS. The sections were covered with the primary antibody diluted in PBS for 1 
hour at room temperature or overnight at 4 °C and rinsed three times for 2 min in 
washing buffer. The sections were then incubated with a biotinylated secondary 
antibody (1:200, Vector) diluted in PBS for 30 minutes at room temperature and rinsed 
three times for 2 min in washing buffer. The biotinylated secondary antibody was 
detected with a complex of streptavidin conjugated to horseradish peroxidase (Strept 
ABComplex/ HRP, Dako) for 30 min at room temperature. To visualize conjugated 
horseradish peroxidase, the sections were covered with AEC solution (Dako) and 
counterstained in Mayers haematoxylin (Sigma). Finally, sections were coverslipped in 
aqueous mounting medium (Aquatex, Merk). 
 
2.4. Scanning electron microscopy (SEM) 
For scanning electron microscopy, male adult (300-400g) Sprague-Dawley rats (n=16) 
were sacrificed 24h or 3d after 3-VO or sham operation.  
Animals were deeply anaesthetized by intraperitoneal injections of 45% ketamine (100 
mg⁄ml), 35% xylazine (10 mg⁄ml) and 20% saline at a dose of 0.32 ml ⁄ 100 g of body 
weight. They were given 200 IU heparin i.p. and perfused transaortically with pre-
warmed plasma substitute (Deltadex 60, DeltaSelect, Pfullingen, Germany, for 10 
seconds at 38°C), followed by perfusion fixation with 1.5% formaldehyde, 2.5% 
glutaraldehyde and 0.01% methylene blue (as label) in 0.1 M phosphate buffer, pH 7.4. 
After 25 minutes, fixation was terminated by perfusion with 5% sucrose in 0.1 M 
phosphate buffer, pH 7.4, for additional 5 minutes. 
Posterior cerebral arteries were isolated and dehydrated in ethanol concentrations of 
30% (2h), 50% (2h), and 75% (O/N). Samples were opened lengthwise, treated with 
OsO4 (4%, 2 hrs), critical-point dried (CPD 30, Bal-Tec), sputtered with ionized gold in 
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a high-pressure argon atmosphere (CDC40), and viewed under a scanning electron 
microscope (Quanta 200, FEI, Kassel).  
 
2.5. Gene expression profiling 
 
2.5.1. Area of interest and selective tissue isolation    
For RNA extraction, animals were submitted likewise to the 3-VO surgical procedure. 
24 h and 3 days after occlusion, the ipsilateral and contralateral part of the PCA within 
the circle of Willis and the posterior communicating artery were isolated and considered 
as our area of interest to study cerebral arteriogenesis, as shown in Figure 13. RNA 
isolation for gene expression analysis was performed for five treatment groups: 24h post 
3-VO; 24h post sham, 3d post 3-VO, 3d post sham, and untreated control group. For 
each treatment group, PCA of 24 animals were isolated and split into three independent 
pools of vessels. Each pool consisted of PCA from 8 animals. Three affymetrix cDNA 
microarrays were hybridized (one array for each pool) for each treatment group (24h 
post 3-VO (n=3), 24h post sham (n=3), 3d post 3-VO (n=3), 3d post sham (n=3) and 
control (n=3). 
Table 1. Gene chip hybridisation experiment study design 
24 h post 3-VO 3 days post 3-VO 24 h post sham  3 days post sham untreated  
n = Pool of PCA  
from 8 animals 
n = Pool of PCA  
from 8 animals 
n = Pool of PCA  
from 8 animals 
n = Pool of PCA  
from 8 animals 
n = Pool of PCA  
from 8 animals 
n = 3 n = 3 n = 3 n = 3 n = 3 
 
2.5.2. RNA isolation and quantification 
Total RNA was isolated using the RNeasy kit (Qiagen). The quantity and quality of 
extracted RNA was further assessed using the RNA 6000 Nano LabChips Kit and 
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) according to the 
manufacturer’s instructions. 
 
2.5.3. Microarray hybridization  
For each array, total RNA (see above) was processed. Biotinylatted cRNA was 
hybridized to affymetrix chips by the Institute for Functional Genomics (Charité, Berlin, 
Germany). Gene expression was analyzed using the commercially available Rat 230 A 
(Affymetrix) Gene Chip containing 15866 probe sets. Hybridization, washing, antibody 
amplification, staining, and scanning of arrays were performed according to the 
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Affymetrix technical manual. Arrays were scanned using the GeneChip System 
(Hewlett-Packard, Santa Cruz, CA) and raw data were processed using GCOS and 
normalized to a global intensity of 500.  
 
2.5.4. Microarray data analysis 
All microarray data were analysed using significance analysis of microarrays [SAM 
(1.21)] with logarithmic transformation to identify differential gene expression after 3-
VO (false discovery rate <10%). The fold change in gene expression levels of each gene 
was calculated as relative to data from sham-operated animals. Significantly deregulated 
genes were further analysed using Ingenuity Pathways Analysis IPA 3.0, which 
identifies physical, transcriptional, or enzymatic interaction networks.  
Ingenuity Pathways Analysis is a web-based software application containing most 
literature knowledge of biologic interactions between gene products 
(http://www.ingenuity.com/products/pathways_analysis.html).   In this study, the gene 
expression profile is presented by the networks generated by Ingenuity: displayed in list 
form the significantly deregulated genes together with the according affymetrix gene 
identification number and fold-change expression values. Furthermore, expression 
profiles of those genes were visualized and presented using Gene Math 1.5.  
In order to understand molecular and biological relations of candidate genes, 
significantly deregulated genes were functionally annotated using the web-based 
Database for Annotation, Visualization, and Integrated Discovery (DAVID) (Dennis, et 
al., 2003).  
  
2.5.5. Target gene promoter analysis 
For 53 genes, DNA sequences from the Ensembl database (ENSEMBLREF) were 
collected, here, a region 5000 bp before and 1000 bp after the transcription start site was 
defined as promoter region and analysed for: (a) putative NF-kB binding site and (b) 
shear stress response elements (SSRE). Both strands were scanned with (a) the 
consensus element KGGRAANTCCC (Sen and Baltimore, 1986) and (b) the potential 
SSRE sites GAGACC and ACCKAGACCAG (Houston, et al., 1999), allowing one 
mismatch and using the program fuzznuc of the EMBOSS package (EMBOSSREF). 
Here R stands for A or G, K for T or G. 
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2.6. Validation of target genes 
 
2.6.1. cDNA synthesis 
500 ng RNA was then reversely transcribed to first-strand cDNA using random 
hexamer primers in 20 μl reactions, ribonuclease inhibitor (0.5 U/μl)  and SuperScript II 
reverse transcriptase (RT) provided in SuperScript First-Strand synthesis kit 
(Invitrogen, Carlsbad, California) following the manufacturer’s protocol.  
 
2.6.2. Quantitative real time PCR 
Amplification was carried out in the ABI Prism 7000 thermocycler (Applied Biosystems) 
with SYBR Green dye (Applied Biosystems) and 2 ng cDNA as template in 25 μl 
reactions. No-template controls and non-enzyme controls were included. Products were 
analysed by gel electrophoresis and inspection of dissociation curves. Quantitative real 
time PCR (qRT-PCR) was performed using gene-specific primers, which were designed 
using the Primer 3 software (Rozen and Skaletsky, 2000), and sequences are provided in 
Table 2 and Table 3. Gene expression data were normalized against HPRT, B-Actin, 
and GAPDH. The PCR profile used for qRT-PCR was 95°C for 10 min and 40 cycles of 
95°C for 15 s, 60°C for 15s, and 30 s for 72°C. The cycle number, at which the emission 
intensity of the sample rises above the baseline, was referred to as Ct (threshold cycle) 
and was proportional to target concentration. Real time PCR data are given as averages 
of three independent experiments, while each experiment was done in triplicate. 
Quantification was performed using single reactions and was analysed by the DART-
PCR method (Version 1.0) (Peirson, et al., 2003) or GED-standard curve method as 
described by Schefe et al. (Schefe, et al., 2006). Mean PCR efficiency of gene-specific 
reactions was used for data analysis. Data are expressed as the means ± standard error of 
the mean. Differences were evaluated with the Mann-Whitney-U-Test; p-values <0.05 
were considered significant. 
 
 
2.7. In situ hybridization  
 
2.7.1. Cloning 
Probes were cloned using the pGEM-T construct (Promega), which carry an ampicillin 
resitance site. Tables of primers may be found in section 2.8.1. Chemically competent 
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DH5α E.coli cells (Invitrogen) were used for the propagation of standard vectors and 
routine subcloning. PCR for the cloning approaches was performed with High Fidality 
Taq DNA polymerase (Roche, PCR system).  
 
2.7.2. Agarose gel electrophoresis 
DNA molecules were separated by gel electrophoresis in gels containing 1-1.5% 
agarose. Standard electrophoresis grade agarose (Invitrogen) was used for analytical 
gels. The electrophoresis was performed in a custom system (Bächler Feintech) at 50 V 
for 20-40 min. The buffer system was TBE (45 mM Tris-borate, 1 mM EDTA, pH 8.3) 
in case of analytical gels and TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) for 
cloning approaches. Ethidium bromide (50 μg/l) was included in the gel to visualize 
DNA bands by UV light (Syngene). 
 
2.7.3. Plasmid isolation and gel extraction 
For plasmid isolations, 3-4 ml 2YT-medium, including proper antibiotics (Ampicillin) 
was inoculated with one colony and cultured overnight at 37 °C while shaking (225 
rpm). Cells grown in 3-4 ml overnight culture were pelleted and plasmids were isolated 
by QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s protocol and 
eluted in 30 μl H2O. If a larger amount of plasmid DNA was desired, 100-200 μl of the 
overnight culture was used to inoculate 100 ml 2YT medium. On the next day, plasmids 
were isolated by QIAGEN Plasmid Maxi Kit (Qiagen) according to the instruction 
manual. Plasmids were eluted in 200 μl dH2O and stored at - 20 °C. 
PCR products were purified by QIAquick® PCR Purification Kit (Qiagen) and eluted in 
30 μl dH2O. Restricted DNA fragments of linearized vectors were separated by gel 
electrophoresis, cut from the gel, extracted using QIAquick® Gel Extraction Kit 
(Qiagen), and eluted in 30 μl dH2O.  
 
2.7.4. Ligation and transformation of chemically competent bacteria 
DNA inserts and linearized vectors were ligated by T4 DNA ligase (Invitrogen) 
according to manufacturer’s protocol. Ligations were incubated overnight at 16 °C and 
diluted 5-fold in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.5) before adding to 
competent cells. 
Chemically competent DH5α E.coli cells (40 μl) were thawed on ice and mixed with 
10-100 nl plasmid. The reaction was pre-chilled for 5-30min, heat-shocked at 42°C for 
45 sec, and subsequently incubated for 2min on ice. The cells were resuspended in 1 ml 
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2YT-medium, incubated at 37 °C for 30min while shaking, and plated onto selection 
agar plates (Ampicillin).  
 
2.7.5. Sequencing and in vitro transcription 
Successful cloning was checked by DNA sequencing (Genome Center, Humboldt-
University, Berlin). For probe generation, 10 µg of each construct were digested by 
NotI or NcoI. Enzymatic reaction was purified by the QIAquick® PCR Purification Kit 
(Qiagen). Finally, probes were amplified by in-vitro transcription using T7 polymerase 
(sense probe) or SP6 polymerase (antisense probe).  
 
2.7.6. In situ hybridization 
In situ hybridization (ISH) was performed on 5µm paraffin embedded tissue sectins 
after postfixing them in 4% PFA in phosphate buffer (pH 7.4; 30min), thereafter rinsing 
with phosphate buffer and digesting with Proteinase K (10µg/ml) in TRIS-EDTA buffer 
(pH 8.0;10min). Sections were hybridized for 18h at 65°C using digoxigenin-labeled 
probes. Immunostaining for digoxigenin (Dig) was performed with an anti-Dig antibody 
conjugated to alkaline phosphatase (Roche, Indianapolis, USA) using NBT/X-
Phosphate as a substrate (blue staining). For TIMP-1, a probe of 336 bp, and for KNT a 
probe of 496 bp was generated. Primers are shown in Table 2 (Section 2.8.1.). 
 
2.8. Assessment of systemic inflammation markers – White blood cell count 
serum amyloid alpha measurement 
To differentiate local cell invasion from systemic post-operative acute phase effects, 
typical markers of a post-surgical acute phase reaction were assessed in the bloodstream 
of all 3-VO, sham, and control animals. Blood samples were taken from each animal 
group and analysed by the Institute for Veterinary Medicine Diagnostics (VMDI, 
Berlin, Germany) for differential WBC count and serum amyloid A levels using flow 
cytometry, and solid phase ELISA with biotinylated monoclonal anti-SAA antibody 
(Tridelta, Ireland), respectively. Analyses were performed in a blinded fashion and 
statistical significance analysed by Student’s t-test. Statistical significance was assumed 
for P < 0.05. 
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2.9. Material 
2.9.1. Primers 
All primers were obtained from Invitrogen Custom primers in a 25 nmol scale (HPSF 
purification) and resuspended in H2O to 100 pmol/μl (100 mM) stock concentration. 
Forward and reverse primers were diluted with RNase/DNase free water (Gibco) to a 
working concentration of 10 μM each. 
Table 2. Primer List 1 
Primer for qRT-PCR Gene Name Sequenz 5´ → 3´ 
Candidate Genes     
rtKNT1-forward1  Kininogen  CACAGGTGGTTGCTGGAGTA  
rtKNT1-reverse1  Kininogen  TCACAATCCGCTGTCAGTTC  
rtTIMP1-forward1  Tissue Inhibitore of Metalloproteinase 1 GCACAGTGTTTCCCTGTTCA  
rtTIMP1-reverse1  Tissue Inhibitore of Metalloproteinase 1 ATCGCTCTGGTAGCCCTTCT  
rtLCN2-forward1  Lipocalin 2 CCCTGTACGGAAGAACCAAG  
rtLCN2-reverse1  Lipocalin 2 GGTGGGAACAGAGAAAACGA  
rtA2MG-forward1  Alpha-2-Macroglobulin TTCTCTTCCACCCAGGACAC  
rtA2MG-reverse1  Alpha-2-Macroglobulin CGAAGAATGGATGGTCACCT  
Housekeeping Genes      
rtGAPDH-forward1 
GAPDH  
Glycerin aldehyd-3-phosphat dehydrogenase CATCAACGACCCATTCATTG 
rtGAPDH-reverse1 
GAPDH  
Glycerin aldehyd-3-phosphat dehydrogenase TTCCCATTCTCAGCCTTGAC 
rtGAPDH-forward2 
GAPDH  
Glycerin aldehyd-3-phosphat dehydrogenase TGCACCACCAACTGCTTA 
rtGAPDH-reverse2 
GAPDH  
Glycerin aldehyd-3-phosphat dehydrogenase GGATGCAGGGATGATGTTCT 
rtHPRT-forward1 
HPRT 
Hypoxanthine-guanine phosphoribosyl transferase CTCATGGACTGATTATGGACAGGAC 
rtHPRT-reverse1 
HPRT 
Hypoxanthine-guanine phosphoribosyl transferase GCAGGTCAGCAAAGAACTTATAGCC 
rtHPRT-forward2 
HPRT 
Hypoxanthine-guanine phosphoribosyl transferase GCAGACTTTGCTTTCCTTGG 
rtHPRT-reverse2 
HPRT 
Hypoxanthine-guanine phosphoribosyl transferase GGCCTGTATCCAACACTTC 
   
Primer forward in 
situ hybridisation Gene Name Sequenz 5´ → 3´´ 
ISH-KNT-forward1 Kininogen AACATCACAGGTGGTTGCTG 
ISH-KNT-forward3 Kininogen AAGAGTGCCCACTCACAGGT 
ISH-KNT1-reverse1/3    Kininogen CCTTTGAGAGTCTGCCCTTG 
ISH-TIMP1-forward2      Tissue Inhibitore of Metalloproteinase 1 TCCCCAGAAATCATCGAGAC 
ISH-TIMP1-forward3      Tissue Inhibitore of Metalloproteinase 1 CTTTGCATCTCTGGCCTCTG 
ISH-TIMP1-reverse2/3   Tissue Inhibitore of Metalloproteinase 1 TGAACAGGGAAACACTGTGC 
ISH-NGAL-forward3   Lipocalin 2 CTGGGTGTCCTGTGTCTGG 
ISH-NGAL-reverse3     Lipocalin 2 CTTGGTTCTTCCGTACAGGG 
ISH-A2MG-forward1      Alpha-2-Macroglobulin  CATTTGCCCTTGCTGGTAAC 
ISH-A2MG-forward2      Alpha-2-Macroglobulin  TCAGCAGCAGAAGGACAATG 
ISH-A2MG-reverse12    Alpha-2-Macroglobulin  GTGTCCTGGGTGGAAGAGAA 
Sequences of oligonucleotides (candidate genes) used as forward or reverse primers for 
qRT-PCR and in situ hybridisation. 
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Table 3. Primer List 2 
Other genes tested Gene Name Sequenz 5´ → 3´ 
rt-tKNG-for1 t_Kininogen GCCTCCAGGATTTTCACCTT 
rt-tKNG-rev1 t_Kininogen CCTTTGAGAGTCTGCCCTTG 
rt-kKNG-for2 k-Kininogen HMW CCAGAAGCAACTTCCCACA 
rt-kKNG-rev2 k-Kininogen HMW GCATCGAGGAGATCAAAATCA 
rtLBP-for1  lipopolysaccharide binding protein ATC GAG TCC AAG CTC CAG AA  
rtLBP-rev1  lipopolysaccharide binding protein GCT GTG ACT GGC AGA GTT TG  
rtC1QB-for1  Complement Component C1Qbeta AAG GAG AGA AAG GGC TCC CC  
rtC1QB-rev1  Complement Component C1Qbeta GAC CCT TGG GGC CAA CTT  
rtCSPG4-for1 Chondroitin sulfate proteoglycan    TCC TGG AGA GAG GTG GAA GA 
rtCSPG4-rev1 Chondroitin sulfate proteoglycan    CGA TCC ATC TCT GAG GCA TT 
rtGPNMB-for1 glycoprotein (transmembrane) nmb TTAATGCCTACTGGCCACAA 
rtGPNMB-for1 glycoprotein (transmembrane) nmb AATTGTGATGGTGGCTCTGA 
rtIGFBP5-for1 Insulin-like growth factor binding protein 5 AAGCTTCCCTCCAGGAGTTC 
rtIGFBP5-frev1 Insulin-like growth factor binding protein 5 AAGGCTTGCACTGCTTTCTC 
rtLU-for1 Lutheran blood group (Auberger b antigen) TGTTCCACTTTGGCTCTGTG 
rtLU-rev1 Lutheran blood group (Auberger b antigen) GCAGCGACTACGAGTAGCAA 
rtNexelin-for1 Nexilin  AATGGGAGTAAGCCCCAAGT 
rtNexelin-rev1 Nexilin  GGTTGGTTGGTTGGTTGTTT 
rtPKD-for1 Polycystin 1 precursor GCAGCACCTTCTTTTTGGTC 
rtPKD-rev1 Polycystin 1 precursor ACAAGGCAGCTTCATTTGCT 
rtPLA1A-for1 Phosphatidylserine-specific phospholipase A1 GATTGCAGTGGACTGGGTTT 
rtPLA1A-rev1 Phosphatidylserine-specific phospholipase A1 GCTCCAAAAGTTTGCTGAGG 
rtRAD-for1 Ras-related associated with diabeties ACATTTGGGAACAGGATGGA 
rtRAD-rev1 Ras-related associated with diabeties TTTCTCAAAGCTGCCCTTGT 
rtTGFB3-for1 Tumor Growth Factor Beta 3 TTGCGGAGAGAGTCCAACTT 
rtTGFB3-rev1 Tumor Growth Factor Beta 3 TTTCCATCACCTCGTGAACA 
rtC3-for1  Complement component 3 CAAAACTGTGGCTGTCCGTA 
rtC3-rev1  Complement component 3 TTGGTCACTGAGGTCTGCTG 
rtICAM1-for2  ICAM-1 Intercellular adhesion molecule 1 CAGACCCTGGAGATGGAGAA 
rtICAM1-rev2 ICAM-1 Intercellular adhesion molecule 1 GTGGGCTTCACACTTCACAG 
rtMCP1-for1 MCP-1 Monocyte chemoattractive molecule 1 TAGCATCCACGTGCTGTCTC 
rtMCP1-rev1 MCP-1 Monocyte chemoattractive molecule 1 CCGACTCATTGGGATCATCT 
rtCARP-for1 Carbonic anhydrase related protein AGTGGGGTTACGAGGAAGGT 
rtCARP-rev1 Carbonic anhydrase related protein AGGGGTCGTATCTGGCTTCT 
rtNOS3-for1 endothelial nitric oxid synthase-3 (eNOS) ATGGATGAGCCAACTCAAGG 
rtNOS3-rev1 endothelial nitric oxid synthase-3 (eNOS) GGATGCAAGGCAAGTTAGGA 
rtMMP2-for1 Matrix-Metalloproteinase-2 ATGACATCAAGGGGATCCAG 
rtMMP2-rev1 Matrix-Metalloproteinase-2 GGAGTGACAGGTCCCAGTGT 
rtMMP9-for1 Matrix-Metalloproteinase-9 CGAGACCTGAAAACCTCCAA 
rtMMP9-rev1 Matrix-Metalloproteinase-9 GCTTCTCTCCCATCATCTGG 
Sequences of oligonucleotides used as forward or reverse primers for qRT-PCR. 
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2.9.2. Antibodies 
Table 4. List of antibodies used for immunhistochemistry 
       
Primary antibodies Company Cat.No. Dilution 
Mouse-PCNA monoclonal Acris SM 1421 P 1:50 
Mouse anti-Ki 67 monoclonal Dako Mib 5 1:50 
Mouse anti-Ki 67monoclonal Dako Tek 3 1:50 
Mouse anti-CD 68 monoclonal Acris BM 4000 1:50 
Mouse- anti-CD 68 monoclonal serotek MCA-341R 1:50 
Cy3 mouse anti-SMC-Aktin monoclonal Sigma-Aldrich C-6198 (1A4) 1:100 
rabbit anti-Kininogen heavy chain polyclonal Santa Cruz 
(H-70)  
sc-25799 1:50 
rabbit anti-Kininogen light chain polyclonal  Santa Cruz 
(M-20)  
sc-25889 1:50 
rabbit anti-Bradykinin antiserum Bachem T-4019 1:1000 
       
Secondary antibodies Company Cat.No. Dilution 
Biotin goat anti-mouse IgG DakoCytomation E0432  1:100 
Cy3 goat anti-mouse IgG Amersham PA43002  1:100 
Cy3 goat anti-mouse IgG Jackson Immuno Research 115-165-166  1:100 
Cy3 goat anti-rabbit IgG Jackson Immuno Research 111-165-144  1:100 
Alexa 488 donkey anti-rabbit IgG   Molecular Probes A-21202  1:100 
Biotin goat anti-rabbit IgG Vector Labs BA-1000  1:100 
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3. Results 
3.1. Characterization of cerebral arteriogenesis in the 3-VO model in the rat 
In order to analyse molecular mechanism of early-phase cerebral arteriogenesis a 
nonlethal model of brain hypoperfusion was employed in rats (3-vessel occlusion 
model). For this purpose, the 3-VO model was established. Surgery did not lead to 
visible neurological defects. As well, no noticeable differences in behaviour were 
detectable on rats post surgery as compared to controls. 3-VO surgery is difficult to 
perform, and successful vertebral artery occlusion is not visible via the paraveterbal 
access. Therefore, successful occlusion had to be verified by Laser Doppler flow 
measurements (LDF). Blood flow was measured in the parietal cortex by LDF, before 
and following bilateral vertebral artery and unilateral carotide artery occlusion. 3-VO 
worked properly if blood flow values declined and remained at the 50 % level as 
compared to blood flow values before surgery, which is exemplified in Figure 9. As 
expected from adaptive brain arteriogenesis, blood flow recovers day to day until at day 
21 it finally archives values comparable to the time-point before occlusion (data not 
shown). 
  
Figure 9. LDF measurement of the parietal cortex  
Successful 3-VO surgery was verified by LDF. A: Prior to 3-VO, B: Following 3-VO blood flow drop to 
around 50 %. The 3-VO model represents a non ischemic hypoperfusion model. 
 
After verifying a successful 3-VO procedure, it was confirmed that blood flow is 
redistributed via the circle of Willis leading to collateral artery growth in the brain. 
Validation of cerebral arteriogenesis was performed by the cerebrovascular latex 
perfusion method, which is also required to identify our area of interest for further 
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morphological and molecular biological studies. Cerebrovascular latex perfusion 
enables diameter measurements of vessels in a situation of complete vasodilation and 
subsequent vasoparalysis, and therefore reflects the true anatomic size of the vessels. 
An increase of the vessel diameter was analysed for three parts of the circle of Willis, 
including the anterior (ACA), the medial (MCA), and the posterior cerebral artery 
(PCA).  
   
 
Figure 10. Vessel diameters in the circle of Willis 7 days post 3-VO or sham 
surgery 
Vessel diameters following maximal vasodilation are given for the anastomoses (ACA, MCA and PCA) 
within the circle of Willis. Diameters are shown for the ipsilateral side and the contralateral side of the 
carotid artery occlusion.  
 
Overall analysis of more than 25 brains per group indicate that application of a high 
dose of adenosin before latex perfusion produced maximal vasodilation that was 
unaffected by intravital differences in vascular tone. At 24h post 3-VO, no significant 
changes in the vessel diameter within the circle of Willis were detectable as compared 
to sham control animals (data not shown), indicating that this time-point is to early for 
collateral growth to become visibly detectable. However, as expected, increase of the 
vessel diameter was found in the circle of Willis, which reached significance at 7d post 
3-VO as compared to sham operated controls (Figure 10). Here, the ipsilateral diameters 
post 3-VO increased significantly from 162 µm (+/- 40 µm) to 205 µm (+/- 45 µm). 
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Contralaterally, diameters increased from 147 µm to 196 µm in comparison to sham- 
operated controls. No significant morphological differences were detectable between 
ipsi- and contralateral regions of the PCA. At 7d post 3-VO diameter of the ACA 
ipsilateral showed changes from 166 µm to 198 µm; the contralateral ACA showed 
diameter increases from 158 µm to 188 µm as compared to sham control animals. 
Likewise to the PCA region no significant morphological differences are detectable 
between ipsilateral and contralateral regions of the ACA. However, a trend indicating 
that the ipsilateral region grew as compared to the contralateral region is detectable, 
although the differences are not significant. Finally, vessel diameter of the MCA region 
do not show differences between 3-VO animals and sham control animals.   
In summary, the PCA show strongest collateral growth in the circle of Willis and it is 
hypothesized that the PCA is the region of interest for analysing arteriogenesis. 
 
3.1.1. Histological evaluation of morphological features of arteriogenesis 
Given that the PCA is recruited as a collateral pathway upon 3-VO to supply the 
hypoperfusion area with blood, enhanced blood flow would induce arteriogenesis and 
morphological features of collateral remodelling should be detectable. Morphological 
features of arteriogenesis were analysed by immunhistological methods to further 
characterize major parameters of arteriogenesis, such as active cell proliferation and 
macrophage invasion. In subsequent experiments, all antibodies were tested on paraffin 
sections from brain with longitudinal sections from the PCA region. 
 
First of all, different commercially available antibodies directed against proliferation 
markers such as Ki67 and PCNA were used. Since PCNA has a longer half-life in 
mitoses than Ki67, it was decided to use an antibody for PCNA to screen for cell 
proliferation in the PCA. Using a PCNA antibody, an increase in vascular cell 
proliferation 24h and 3d after 3-VO was detectable (Figure 11A-D), demonstrating that 
cell proliferation already occurs in early-phase cerebral arteriogenesis.  
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Figure 11. Immunostaining for PCNA and CD68 in the PCA region 
A-D: Staining for proliferation marker PCNA (red). Hematoxylin staining of nucleus (blue) A: PCA 
region 24h post 3-VO surgery, B: PCA region 24h post sham surgery, C: PCA region 3 days post 3-VO 
surgery, D: PCA region 3 days post sham surgery. E-H Staing for macrophage marker CD68 (red). 
Hoechst staining of the nucleus (blue). Staining for smooth muscle actin (green). E: PCA region 24h post 
3-VO surgery, F: PCA region 3 days post 3-VO surgery, G: PCA region 24h post sham surgery, H: 
Magnification of PCA region 24h post 3-VO surgery. 
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Only a scarce distribution of proliferating cells was detectable on sections from sham 
control animals.  Differences in numbers of proliferating cells between the posterior 
cerebral arteries on the ipsi- or contralateral side of the ligated carotid artery could not 
be observed, showing that cell proliferation in the PCA occurs bilaterally, which is in 
line with the findings for PCA diameter growth. Interestingly, a closer look on the 
histological sections reveal that 3 days after 3-VO endothelial cells seem to bulge into 
the lumen (Figure 11, Arrow), which is neither detectable 24 hours after 3-VO nor on 
sections of sham control animals. 
 
Second, antibodies were applied against the macrophage marker CD68 (ED-1 in rat) to 
analyse for enhanced monocyte transmigration in the PCA in early-phase cerebral 
arteriogenesis. As described in section 1.3., macrophage invasion is an important 
process for inducing arteriogenesis. Indeed, CD68 staining showed a significantly 
increased number of invading macrophages 24h and 3d post 3-VO (Figure 11E, 11F) in 
the perivascular space compared to controls (Figure 11G). Accumulation of CD68-
positive cells was detected in the adventitia as well as in the surrounding arachnoidea in 
close proximity to the growing PCA. Positive CD68 staining was also obtained at the 
endothelial cell layer, indicating adhesion of macrophages to endothelial cells (Figure 
11H). 
 
In summary, histological analysis of the PCA (24h and 3 days) post 3-VO reveal typical 
features of arteriogenesis. 
 
3.1.2. Electronmicroscopical analysis of flow activated endothelial cells 
Enhanced blood flow via the PCA post 3-VO, results in increased fluid shear stress. 
Fluid shear stress is the driving force of arteriogenesis (section 1.3.), resulting in 
endothelial cell activation. Activation of endothelial cells by enhanced blood flow in the 
growing collaterals of early-phase arteriogenesis was analysed by applying scanning 
electron microscopy. Thus, 24 hours and 3 days after 3-VO or sham surgery PCA 
vessels were selectively removed, and a novel technique was developed to prepare the 
PCA for microscopy (see section 2.4. and 4.1.4.). The PCA was opened lengthwise 
using iris scissors, and different tissue glues were tested to adjust the opened vessel on a 
glass slide (Figure 12A, 12B). Second, critical point drying in carbon dioxide and 
subsequent spotting with ionized gold particle under an argon atmosphere allowed 
visualization of the endothelial cell layer.  
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Figure 12. Scanning electron microscopy of the endothelial layer of the PCA  
A: PCA is opened lengthwise and mounted on glass slide. B: Microscope zoom allows visualization of 
the endothelial cell layer. C: 3 days post 3-VO surgery (5000x), D: 3 days post sham surgery (5000x), E: 
3 days post 3-VO surgery (10.000x), H: 3 days post sham surgery (10.000x). 
 
Scanning electron microscopy, visualizes the PCA endothelial cell layer of sham 
animals, which exhibit a smooth and flat cellular surface (Figure 12D, 12F, previous 
page). In comparison, a cobblestone-like pattern was detectable in the growing PCA 3d 
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post 3-VO (Figure 12C, 12E). On closer inspection, the endothelial cells reveal that this 
cobblestone-like pattern is formed by a protrusion of the nucleus. In addition, 
endothelial cells of the PCA 3d post 3-VO are divided by a demarcation line. Here, cell 
borders show pronounced structures, and is in contrast to sham animals. Furthermore, at 
3d post 3-VO, big globular-like objects are frequently visible between cellular borders. 
At 24h post surgery, the endothelial cell layer of the PCA in 3-VO animals was smooth 
and flat and comparable to the endothelial cell layer of sham animals (data not shown). 
 
3.2. Molecular mechanisms of early-phase cerebral arteriogenesis 
Vessel diameter measurements and morphological characterization of growing 
collaterals identified the PCA in the circle of Willis as the region of interest, which 
showed typical features of arteriogenesis; however, little is known about the molecular 
mechanisms of early-phase cerebral arteriogenesis. Thus, the PCA was chosen for 
further analysis of the molecular mechanism of early-phase cerebral arteriogenesis. 
Despite challenging anatomical conditions in the brain, the 3-VO model permits the 
selective preparation of a growing collateral artery (PCA), which is located on the 
surface of the brain (section 1.5). This study describes the first genomic approach 
focused on a selective isolation of a growing collateral artery and managed to harvest 
the PCA 24 h and 3 days after 3-VO. Subsequently, RNA was isolated for identification 
of differentially expressed genes during adaptive cerebral arteriogenesis (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Selective isolation of the PCA out of the circle of Willis in the rat brain  
Angiography of the circle of Willis in the rat brain. Vessels of the area of interest (PCA/Pcom) which 
were isolated are marked by red bars. Vessels were swiftly isolated and immediately stored in `RNA 
later´ (Ambion) for RNA preservation. 
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3.2.1. Genomic profiling 
A global genomic profiling approach was performed using the Affymetrix chip 
technology (section 2.4.4) to analyse the patterns of the initial start up phase of 
arteriogenesis. At NCBI Gene Expression Omnibus, raw data of the chip hybridisation 
experiment are available, where series record GSE6189 provides access to all 
expression data. At 24h post 3-VO, significance analysis of microarrays (SAM) 
identified 91 genes as upregulated and 73 genes as downregulated (n=164 out of 15.866 
probe sets) as compared to sham-operated controls. Expression differences are 
considered significant, as SAM integrates for each gene random permutations of the 
transcription values of all samples and the expression deviation between biological 
replicas. 
However, global gene expression profiles raise the problem that extreme amounts of 
data are produced without any basic concept. In order to understand molecular patterns 
of early-phase arteriogenesis and to identify relevant target genes, which have 
functional relevance for arteriogenesis, several bioinformatics software tools were used 
to structure the various genomic data.  
 
First, genes identified by SAM as deregulated were grouped into genetic networks by 
knowledge-based analysis of physical, transcriptional, or enzymatic interactions by the 
Ingenuity Pathway Analysis software tool (IPA). Here, IPA demonstrates that gene 
expression of cerebral arteriogenesis 24h post 3-VO can be clustered into six 
functionally related networks. Networks designed by IPA are presented in Figure 14 
(next page) showing deregulated genes, where colors indicate the degree of increased 
expression in red, decreased expression in green, and unregulated gene expression in 
white. Network 1 comprises genes involved in cellular movement and cellular 
development. Genes in network 2, 3, and 5 are related to cellular growth, cellular 
proliferation, and cancer. The functional clustering to cancer development might be 
confusing. However, this relation make sense, as genes shown here are responsible for 
angiogenesis and vessel formation as a basic mechanism for cancer development, and, 
interestingly, reappear in collateral development. Furthermore, Network 3 is relevant for 
cardiovascular system development. Networks 4 and 6 show genes related to 
inflammatory processes and molecular transports.  
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Figure 14. Ingenuity network analysis of early-phase cerebral arteriogenesis   
Identification of transcriptional, enzymatic or physical interaction of deregulated genes 24h post 3-VO. 
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Network analysis shows that all six functional networks are related to each other on a 
superordinate level and to cardiovascular system development and function (Figure 
14H). Second, molecular analysis for patterns of early-phase of cerebral arteriogenesis 
aimed at summarizing expression values of those genes involved in the six distinct 
networks. Therefore, all genes were clustered into groups corresponding to the networks 
and expression values visualized by GeneMath for each biological replicate, as 
presented in Figure 15 (next page) together with the according fold change value (24h 
post 3-VO).  
Visualized values of those genes demonstrate homogeneous distribution within the 
groups (Figure 15), indicating the high reliability of the expression data. Although 3d 
post 3-VO, most genes were not significantly deregulated; graphical visualization of 
listed genes shows clearly a similar trend of genes 24h post 3-VO and 3d post 3-VO. At 
24 hours post 3-VO, differently expressed genes show that highest expression values 
were between 3 and 4 fold change deregulated. The following genes are to be 
mentioned in this context: secreted phosphoprotein (network 1), phospholipase A1 
member A (network 2), serin phospholipase A1 (network 2), glycoprotein nmb (network 
3, 6), methallothionein (network 3), topoisomerase II alpha (network 3), chemokine 
ligand 14 (network 3), ceruloplasmin (network 4), alpha-2 macroglobulin (network 4), 
complement component 3 (network 4), chemokin-ligand 6 (network 5), crystallin alpha 
A (network 6), FC fragment of IgG (network 6) and leucocyte Ig-like receptor B 
member 3 (network 6) (Figure 14, Figure 15). For more detailed analysis and literature 
research affymetrix identifiers for all genes are given in Figure 15 as well. 
 
Moreover, in particularly noticeable at 24h post 3-VO is the expression of kininogen, 
which is the most strongly upregulated gene in this expression profile (66.4 fold 
change) and is involved in networks 3 (cellular growth and proliferation) and 6 
(inflammation) (Figure 15). Lipocalin 2 and Tissue inhibitor of metalloproteinase-1 
(network 1) showed second and third highest expressions, respectively, and are 
upregulated more than 6 fold.  
 
In summary, IPA analysis demonstrates that genes deregulated in early-phase cerebral 
arteriogenesis are part of related networks assigned to three major functions or 
categories: cellular movement, inflammationy and cellular growth/proliferation (Figure 
15). 
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Figure 15. Genomic profile of early-phase cerebral arteriogenesis  
Visualization of the genomic expression profile. Genes deregulated in early-phase cerebral arteriogenesis 
are clustered in 6 functional networks related to cardiovascular system development. Figure shows 
upregulated genes in red and downregulated genes in green.  Expression profile shows homogeneous 
distripution within the groups. Fold change values are given 24h post 3-VO surgery as compared to sham 
controls. Affymetrix identifiers are given for gene specification. 
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The overall expression profile so far indicates a common pattern for vascular 
remodelling, obtained from angiogenesis and for arteriogenesis, which points to a 
number of highly upregulated regulatory genes involved. Indeed, those patterns provide 
the first clue about the mechanisms of early-phase cerebral arteriogenesis. 
 
To further analyse those genes involved, a detection software for overexpressed Gene 
Ontology (GO) -categories was used (DAVID database). The DAVID Bioinformatic 
database was applied to annotate all known genes involved in the network, as shown 
above (Figure 15) to biological function and molecular function.  
Biological function annotation summary showed that highest significance levels were 
assigned to the GO-categories `response to pathogens´, `response to wounding´, 
`immune response´, and `defense response´ (Table 5A). In conclusion, early-phase 
cerebral arteriogenesis includes many genes involved in inflammatory processes. 
Detailed list of all genes annotated to the most characteristic GO-categories are given in 
the appendix (Page 94). Studying GO-categories more closely showed, for example, 
genes involved in inflammatory processes are: alpha-2 macroglobulin, chemokine 
ligand 14, complement components 1 and 3, lipoprotein binding protein. In this context, 
it is notable that some genes are grouped to the GO-categories `Mononuclear cell 
proliferation´ and `leukocyte mediated immunity´. Mononuclear leucocyte recruitment 
and proliferation is a major feature of arteriogenesis, and here genes are involved, such 
as kininogen and complement component 1, q subcomponent, beta polypeptide. 
Frequently, genes were annotated to multiple functions, as was kininogen, which is 
likewise functionally annotated to `cell differentiation processes´ and Tissue inhibitor of 
metalloproteinase-1 (TIMP-1), which is likewise functionally annotated to `regulation 
of cell proliferation` and `system development´. Biological function annotation also 
show that 24h post 3-VO many genes are related to processes, such as `cell 
proliferation´, `cell differentiation´ and `system development´. To quote an example 
these functional groups contained genes, such as interferon induced transmebrane 
protein 1, glycoprotein nmb and surprisingly neuronally related genes, such as 
neurogenic differentiation 1, and semaphorin 4f.  
 
Biological function annotation to significantly repressed genes showed several genes 
related to `muscle development´ and `muscle contraction´ (Table 5B), such as 
smoothelin and myosin light chain. Similar to biological processes identified from 
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upregulated genes, some downregulated genes (basically inhibitors) were functionally 
related to processes, such as `system development´ and `cell proliferation´ as well.  
 
Table 5. DAVID biological function annotation summary 
  
  
A: Biological function annotation of genes upregulated. B: Biological function annotation of genes 
downregulated. Genes upregulated annotated highly significant to biological functions related to 
inflammatory processes. Upon genes downregulated most were significant related to muscle development 
and construction. 
 
In summary, biological function annotation using DAVID bioinformatic database 
demonstrates that the main focus of early-phase cerebral arteriogenesis is on 
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inflammatory processes. Furthermore it is shown, that 24h post 3-VO cellular 
proliferation, cellular differentiation and de-differentiation are relevant processes for 
collateral growth.  
 
Table 6. DAVID molecular function annotation summary   
 
Annotation for molecular function of deregulated genes revealed a very significant cluster for protease 
inhibitors.  
 
Finally, annotation of deregulated genes to molecular function at 24h post 3-VO 
revealed a significant cluster of protease inhibitor genes of which kininogen, alpha-2 
macroglobulin (A2M) and Tissue inhibitor of metalloproteinase-1 (TIMP-1) had lowest 
p-values (0,00071, Table 6). Genes of these protease inhibitors show the strongest 
deregulation and are involved in most functional networks generated by Ingenuity 
(Figure 14, 15). In silico analysis and DAVID database analysis clearly show that 
protease inhibitors are multifunctional proteins, involved in most processes of 
cardiovascular system development (see above), and are expressed in many 
physiological and pathological conditions. Hence, protease inhibitors are investigated in 
more detail in the following paragraph. 
 
Protease inhibitor Kininogen (66.1 fold change, Figure 15), by far the strongest gene 
expressed in early-phase cerebral arteriogenesis regulates the homeostasis of 
extracellular matrix digestion in vascular remodelling. Furthermore kininogen is the 
substrate of kallikrein which liberates the highly vasoactive compound bradykinin 
(section 1.8.).  
Likewise, TIMP-1 (6.1 fold change, Figure 15), the third most upregulated gene in the 
expression profile, is a protease inhibitor responsible for regulating matrix 
metalloproteinase activity. Lipocalin 2 (LCN2), a non-protease inhibitor and the second 
most deregulated gene in this profile (6.8 fold change, Figure 15), is shown to be 
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functionally related to TIMP-1 in extracellular matrix degradation. TIMP-1 also 
regulates the digestion of extracellular matrix in remodelling and exhibits growth factor 
activity, involved in other processes like modulating cell proliferation, migration, and 
leucocyte survival.  
Finally, in network 3, expression of alpha-2 macroglobulin (A2M), another protease 
inhibitor, is reported, which is also involved in inflammatory processes, and was shown 
to be upregulated 3.2 fold 24h post 3-VO (Figure 15).  
 
In conclusion, for those protease inhibitors, a multitude of functions are indicated and 
therefore protease inhibitors and related proteins were further validated by molecular 
analysis.  
 
3.2.2. Promoter analysis 
Data obtained in this study help to understand the molecular mechanisms of early-phase 
cerebral arteriogenesis and to identify genes, which may be involved in initiating 
collateral growth, but one important step is still not well understood. Mechanical force 
exerted by blood flow activates gene expression in endothelial cells, however, the 
following main driving stimulus governing the expression of relevant key players and 
maker genes of early-phase cerebral arteriogenesis is not yet known. Do forces acting 
on the endothelium induce expression of genes in a paracrine manner leading to 
inflammatory processes, or is gene expression 24h post 3-VO continuously directed by 
a flow-induced process?  
 
Hence, a promoter analysis was performed for 53 most strongly deregulated genes, to 
identify inflammation-regulated genes by their NF-kB binding sites or flow-regulated 
genes by their shear stress response elements (SSREs). Therefore, a region from 5000 
bp before to 1000 bp after the transcription start site of target genes was browsed for 
putative NF-kB binding site (inflammatory regulation) and SSREs (flow-mediated 
regulation). 
 
Of 53 deregulated genes, promoter analysis identified 42 genes that contained at least 
one NF-kB binding site and only 5 genes containing at least one SSRE, which are listed 
in Table 7. However, all genes containing SSREs as well exhibit one NF-kB binding 
site. Noticeable is the TGF-beta 3 gene, which was 0.48 fold downregulated exhibits 3 
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SSREs and 2 NF-kB binding sites. Furthermore, a gene related to neurogenesis, such as 
Neurologenic differentiation factor 1 exhibit a SSRE. 
Among our strongly deregulated proteinase inhibitors Kininogen, TIMP-1 and A2M, and 
the functionally related Lipocalin 2, all exhibited more than one NF-kB binding site and 
non of them an SSRE.  
 
Table 7. Promoter analysis 
Sam Analysis 24h 3VO 
positive 
deregulated 
negative 
deregulated 
                               
total 
10 % False Positive Rate 73 91 164
Promoter Analysis of 53 
Potential Candidate Genes 
positive 
deregulated 
negative 
deregulated total  
Genes with NF-kB binding site 27 15 42
Shear Stress Response Elements 3 2 5
Promoter Analysis of Target 
Genes 
fold change (Array 
analysis) 
Number of NF-kB 
binding sites  
 
Number of SSRE 
Kininogen 66.37 3 / 
TIMP-1 6.06 9 / 
Lipocalin 2 6.76  2 / 
Alpha-2-Macroglobulin 3.21 4 / 
   
Neurogenic differentiation factor 1 2.59 2 1 
ELAV-like protein 4/ Hu-antigen D 2.91 2 1 
l-gicerin 2.69 3 1 
similar to Small inducible 
cytokine A6 (CCL6) 0.52 1 
 
1 
Transforming growth factor 
beta 3 (TGF-beta 3) 0.48 2 
 
3 
Promoter analysis was performed for 53 early-phase cerebral arteriogenesis target genes and promoter 
region browsed for NF-KB binding sites or SSREs. Most candidate genes have at least one NF-kB 
binding site within their promoter region. Only 5 candidate genes exhibit a putative SSRE in the promoter 
region. However, all genes exhibiting an SSRE have as well at least one NF-kB binding sites in the 
promoter region. 
 
Due to the overall impact of inflammation in early-phase cerebral arteriogenesis and the 
fact that most genes contained at least one NF-kB binding site, it was decided to 
continue molecular analysis by focusing on protease inhibitors. Here, strong expression 
values and the potential use for a therapeutical stimulation of arteriogenesis have been 
considered as well for the decision to study protease inhibitors in more detail.  
 
3.2.3. Inflammatory Processes  
Many genes involved in early-phase arteriogenesis were clustered and annotated to 
inflammatory processes, which is in line with the expression profile of Lee et al. for the 
initial phase of arteriogenesis in the mice hind limb. However, it was considered that 
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inflammatory genes are deregulated because of a systemic post-operative acute phase 
reaction. Each form of injury or tissue damage inevitably also causes an inflammatory 
response which may result in an acute phase reaction. An acute phase reaction is 
characterized, among other things, by an increase in the numbers of circulating white 
blood cells (e.g. neutrophils and macrophages). Furthermore, the liver responds by 
producing a large number of acute-phase reactants, such as C-reactive protein and 
serum amyloid A (SAA).  To rule out acute phase reaction as a relevant cause of 
changes in the gene expression profiles, white blood cell count (WBC) was performed 
and rat serum amyloid-alpha (SAA) was determined, which correlates with the human 
CRP.  
  
Figure 16. White blood cell count 
Figure indicates that white blood cell number are unchanged whithin all animals comprised in the study 
for early-phase cerebral arteriogenesis (24h post 3-VO). 
 
WBC was not altered in 3-VO animals and control animals after 24h and 3d post 3-VO 
(Figure 16). Serum amyloid alpha was below detection limit in all groups (data not 
shown). 
 
3.2.4. Validation of target genes significantly deregulated in the PCA at 24h post 
3-VO  
Quantitative real-time RT-PCR was carried out with the same RNA samples used for 
microarray analysis to validate the results of the microarray analysis. Figure 17 shows 
expression levels of the protease inhibitors kininogen, TIMP-1, A2M, and the non-
protease inhibitor LCN2 as obtained by qRT-PCR, which validated the array 
hybridisation data and confirmed a significant increase in mRNA levels during early 
cerebral arteriogenesis in the ipsilateral PCA 24h post 3-VO compared to the sham 
group (Figure 17A-D). 
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More than 10 genes, which were found deregulated by SAM analysis, were validated by 
qRT-PCR. All confirmed the expression level shown by the affymetrix array 
hybridisation experiment (data not shown), indicating the high reliability of data 
obtained from the chip hybridisation experiment. In addition, gene expression levels for 
kininogen, TIMP-1, A2M, and LCN2 were analysed by qRT-PCR in tissue samples from 
the PCA contralateral to the ligated carotid artery. Here, the increase in mRNA 
expression levels of all four genes was found to be similar to the one in the ipsilateral 
PCA region. 
  
Figure 17. Validation of target gene expression by qRT-PCR 
Validation of mRNA expression of the protease inhibitors kininogen, TIMP-1 and A2M and the related 
protein lipocalin 2. qRT-PCR was performed for RNA obtained from the ipsilateral and contralateral site 
of the carotid occlusion.  
 
In order to control reliability of the genomic profile, expression of sham-operated 
animals and intact controls were compared. No significant expression differences were 
detectable (Figure 17). Importantly, expression levels of genes validated by qRT-PCR 
within each of the three replicates of each experimental condition were upregulated in a 
similar range, indicating a similar expression pattern within the same groups. 
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As protease inhibitor expression was validated by qRT-PCR, this study aimed at 
localizing potential target gene expression in early-phase cerebral arteriogenesis 24h 
post 3-VO. Probes for kininogen, A2M, TIMP-1, and Lipocalin 2 mRNA were 
generated for in situ hybridisation, which allows localization of mRNA expression in 
the vascular tissue of the PCA region. Here, it was managed to localize mRNA 
expression for TIMP-1, which recently was identified as being upregulated during 
arteriogenesis in the dog heart (Pipp, et al., 2004) and postulated to be a marker of 
coronary arteriogenesis. Furthermore, kininogen mRNA expression was localized by in 
situ hybridisation, since kininogen was one of the most strongly induced genes we 
identified. For Lipocalin 2 and A2M it was not managed to show mRNA expression in 
the growing PCA.  
In situ hybridisation showed a high TIMP-1 and kininogen mRNA staining intensity in 
the vascular wall of the PCA 24h post 3-VO (Figure 18A, 18D) compared to sham 
control (Figure 18B, 18E).  
  
Figure 18. Localisation of target gene expression in the growing PCA post 3-VO 
surgery by in situ hybridisation 
In situ hybridisation using DIG labled probes for TIMP-1 and kininogen mRNA on rat brain paraffin 
sections showed a positive signal in the vascular wall of the PCA 24h post 3-VO.  
The expression of TIMP-1 and kininogen is detectable in endothelial cells, smooth muscle cells and tissue 
of the arachnoidea.  
 
Increased expression levels of TIMP-1 and kininogen mRNA were detected in 
endothelial cells, smooth muscle cells, and adjacent meningeal tissues (arachnoidea). 
Results                                                                                                                                    53 
  
 
Using sense probes for TIMP-1 and kininogen, no staining was detectable (Figure 
18C+18F), indicating specificity of the probes.  
In summary, molecular analysis of growing collaterals (PCA) in the brain identified 
kininogen and TIMP-1 as strong deregulated gene within the vessel wall 24h post 
occlusion.  Excessive data base research, in silico analysis, and the use of bioinformatic 
databases implicate a multifunctional role of kininogen and TIMP-1, which are involved 
in many biological pathways. Promoter analysis indicates regulation of inflammatory 
process in the context of kininogen and TIMP-1 gene expression, and previous studies 
already demonstrate that arteriogenesis is initiated by inflammatory processes 
(Buschmann, et al., 2003). In this study, protease inhibitor mRNA expression was 
validated by qRT-PCR and kininogen, and TIMP-1 mRNA expression was localized in 
the growing PCA 24h post 3-VO, which identified Kininogen and TIMP-1 as marker of 
early-phase cerebral arteriogenesis.   
 
 
3.3. Functional Analysis of the relevance of the kininogen signaling pathway for 
arteriogenesis 
Kininogen and TIMP-1 were identified as marker genes of early-phase cerebral 
arteriogenesis. The third part of this work is intended to give insight into the functional 
relevance of a newly identified target gene for collateral growth. For many reasons, 
kininogen appeared to be a much more attractive target and was chosen as target for 
functional analysis. In particular, kininogen-bradykinin signaling is involved in 
vasodilation, in inflammatory processes, in leucocyte recruitment, and in processes of 
angiogenesis (section 1.8.). However, the bradykinin signaling pathway has not been 
analysed before in the context of arteriogenesis. Since this is a study based on a 
genomic analysis, it is much more reliable, analysing signaling pathways on transgenic 
lose of function models, than using pharmacological inhibitors. Hence, studies were 
performed by using the bradykinin receptor B1, the bradykinin receptor B2, and a newly 
developed strain with a double KO of the bradykinin receptor B1 and B2. However, the 
problem arose that the 3-VO model is yet not applicable to mice, for technical reasons 
(section 1.5). To ascertain the involvement of the kininogen-bradykinin signaling in 
arteriogenesis, the technically available femoral artery occlusion model was used. The 
femoral artery occlusion model is the best-characterized model for analysing 
arteriogenesis and is regularely used for the purpose of in vivo verification of data 
obtained in arteriogenesis research. In particular, the femoral artery ligation model 
Results                                                                                                                                    54 
  
 
enable the direct measurement of arteriogenesis by the microsphere technique and 
perfusion (van Royen, et al., 2002) (section 1.6.).  
 
3.3.1. Kininogen expression is enhanced in hind limb arteriogenesis 
Certainly, one could expect differences in the molecular mechanism of arteriogenesis in 
the brain and the hind limb, however, this study is merely intended to answer the 
question whether kininogen has a fundamental relevance for processes of collateral 
growth in general. To identify whether kininogen mRNA expression in early-phase 
arteriogenesis is comparable to early-phase arteriogenesis in the brain, qRT-PCR was 
performed on RNA isolated from complete adductor muscle of the ligated and unligated 
hind limb. The adductor muscle contained the collaterals in the hind limb, which make 
selective isolation of collateral vascular tissue very problematic. qRT-PCR show that 
kininogen is more than 2 fold higher expressed in the adductor muscle of the ligated leg 
as compared to the unligated leg (Figure 19). 
 
 
  
Figure 19. Kininogen expression in the mouse hind limb 24h post femoral artery 
ligation 
Kininogen mRNA expression is upregulated in the adductor muscle tissue, which contains the collateral 
vessel region, in the ligated leg, as compared to the unligated leg. 
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3.3.2. Collateral growth following femoral artery ligation in bradykinin recetpor 
mutant mice 
The capacity for collateral growth was measured by microsphere infusion 7 days after 
femoral artery occlusion (section 2.2.1.). Values obtained in the ligated left leg were 
normalized against the collateral conductance of the unligated right leg (100%) to 
evaluate arteriogenesis. The extent of peripheral arteriogenesis was measured in 
C57BL/6 wild type mice and compared with data obtained from different C57BL/6 
bradykinin receptor KO mice strains. Data are shown in Figure 20. All bradykinin 
receptor KO mice strains exhibit a significantly reduced collateral capacity in 
comparison to the wild type mice.  
   
 
 
Figure 20. Degree of collateral capacity in bradykinin receptor KO mice 
Collateralization is given for WT, B1 receptor KO, B2 receptor KO and B1/B2 receptor double KO 7 
days post femoral artery occlusion. A degree for collateral capacity is measured under maximal 
vasodilation by pressure controlled infusion of fluorescent microsphreres of different size mice. Under 
pressure controlled conditions counting fluorescent microspheres serves as a value for assessing 
arteriogenesis. Microspheres within the ligated leg were counted by FACS analysis and normalized 
against reference samples and adjusted to the number of microspheres within the unligated leg (100 %). 
Here mean collateral capacity is given in relative units.   
 
In particular, bradykinin receptor B1 KO mice (22.41 units) exhibit a more than 50 % 
reduced collateral capacity as compared to WT mice (56.17 units), and the difference 
between those two mice strains was about 33.76 units (Figure 20). Hence, the B1 KO 
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mice had the strongest phenotype and arteriogenesis seem to be severely reduced. The 
bradykinin receptor B2 mice (41.53 units) also exhibit a significantly reduced collateral 
capacity as compared to wild type mice. However, the differences in collateralization 
between bradykinin receptor B2 KO mice and wild type mice (14.64 units) is much 
lower, as compared to the difference of the collateralization between bradykinin 
receptor B1 KO mice and wild type mice.  
Interestingly, for the bradykinin receptor B1/B2 double KO mice, collateral capacity is 
shown to be reduced by 19.43 units as compared to wild type mice (Figure 20). Hence, 
no cumulative reduced collateral capacity was found, and the phenotype of double 
receptor KO mice remains between the phenotype of the bradykinin B1 ad B2 receptor 
KO mice. As shown in figure 20, the difference of the double receptor KO mice is 
significantly higher as compared to the bradykinin B1 KO mice, but the differences to 
the bradykinin receptor B2 KO mice is not significant.   
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4. Discussion 
This work intended to characterize the morphological and molecular patterns of early-
phase cerebral arteriogenesis. Thus, results would enable us to identify novel target 
molecules that initiate arteriogenesis, which could contribute to the development of a 
noval therapeutic strategy to induce collateral growth. The 3-VO model was used, 
which is the first model to study cerebral arteriogenesis under controlled conditions 
(Busch, et al., 2003), and for which clinical relevance by therapeutically induced 
collateral growth has been shown (Schneeloch, et al., 2004). 
First, data shown here identify the PCA as region of interest (growing collateral) and 
describe the morphological features of the PCA post 3-VO in the adult rat brain. 
Characteristic features of the arteriogenic process in the PCA were shown, such as 
vascular proliferation and monocyte invasion. Direct evidence was given for endothelial 
cell activation upon 3-VO by scanning electron microscopy (SEM) in growing 
collaterals of the brain. 
 
Second, this work summarizes the molecular mechanisms, which underlie the initiation 
processes during early-phase cerebral arteriogenesis. For the first time it presents a 
comprehensive gene expression profile of early-phase collateral artery growth. 
Bioinformatic databases, functional annotation, and validation of expression data 
indentified TIMP-1 and kininogen as marker of collateral growth in the brain. 
 
Third, this study gives direct evidence for the functional relevance of kininogen-
bradykinin signaling during arteriogenesis, measured in the well-characterized model of 
femoral artery ligation in bradykinin receptor KO mice. 
 
4.1. 3-VO model was successfully reproduced in this study 
Collateral arteries in the brain offer a circumventing blood flow to maintain brain 
oxygenation and substrate supply when a primary vessel in the cerebral arterial tree is 
critically occluded. The circle of Willis is the most capable collateral system in the 
brain, providing a low-resistance link between the four main supplying arteries (two 
carotid arteries and two vertebral arteries) (Hossmann, 2003). To study collateral 
growth in the brain, it was necessary to reproduce the non-ischemic 3-VO model for 
cerebral arteriogenesis, which has previously been established by Busch et al (Busch, et 
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al., 2003). Cerebral arteriogenesis in the circle of Willis is induced by a combination of 
unilateral carotid artery and bilateral vertebral occlusion (3-VO). 3-VO lead to reduced 
cerebral blood flow (CBF) in the ipsilateral hemisphere of about 50 %, as compared to 
sham controls. Ongoing occlusion time did not increase CBF any higher (Figure 9). 
This result reflects the observation of Busch et al., who found that post 3-VO blood 
flow remained at the 50 % level, which is of crucial importance to induce adaptive 
arteriogenesis. Only a lasting reduction in CBF simulates the situation of hypoperfusion 
after occlusion of a major artery, which occurs previously to stroke. In fact, Busch et al. 
showed that despite reduced CBF of about 50 %, rats did not exhibit behavioral changes 
or disabilities. Likewise rats, which underwent 3-VO in our study, did not show any 
neurological deficits. Furthermore, Busch et al. already confirmed that rats do not have 
noticeable infarct areals post 3-VO, as obtained by histological evaluation of cryostat 
sections using cresyl violet staining, RhoB immunohistochemistry, and TUNEL.  
 
4.1.1. ACA and PCA are recruited as collateral pathways post 3-VO 
Continuous hypoperfusion leads to a redistribution of blood flow via the circle of 
Willis, basically by recruiting the ACA and PCA. Here, blood flow seemed to be 
redistributed mainly via the PCA in order to supply the hypoperfused area with blood. 
The PCA diameter increases within 7 days significantly by 37 %, as compared to sham 
controls (Figure 10). Hence, increased shear force generated by enhanced blood flow 
successfully induces cerebral arteriogenesis in the PCA. These results verify data 
obtained by Busch et al., however, in contrast to previous findings, here it was shown 
that both PCA regions, ipsilateral and contralateral of the carotid artery occlusion, 
significantly increased in diameter. Busch et al. showed that the vessel diameter of PCA 
contralateral increased only to a lesser degree. In fact, the strong bilateral PCA 
outgrowth observed in this study seems logical, since the PCA of both hemispheres has 
to be recruited as a collateral pathway in order to supply the hypoperfused area with 
blood. Furthermore, in our study blood flow seems to be redistributed as well via the 
anterior part of the circle of Willis. The ACA increases significantly in diameter within 
7 days by around 32 µm. The anterior part as well as the posterior part interconnects the 
normal perfused area contralateral of the carotid occlusion with the ipsilateral 
hypoperfusion area (Figure 10). Blood flow is redistribution via the ACA as well as the 
PCA, which explains arteriogenesis observed in both brain regions. However, since 
recruitment of the PCA is the shorter way to supply the hypoperfusion area with blood 
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as compared to the ACA, blood flow is higher in the PCA according to the law of 
Hagen-Poiseuille (Figure 2), which indicates that blood flow is inversely proportional to 
the vessel length. A vessel having twice the length of another vessel (and each having 
the same radius) will have twice the resistance to flow. Therefore, blood flow via the 
PCA should be higher. Indeed, outgrowth of the PCA was larger and the PCA was 
chosen as area of interest for analysing morphological and molecular patterns of early-
phase cerebral arteriogenesis.   
4.1.2. Immunhistochemical characterization of early-phase cerebral 
arteriogenesis 
The best time point for analysing gene expression of growing collateral vessels in the 
brain has so far not been known. Vessel growth becomes detectable only seven days 
after 3-VO in the PCA; however, immediately after vessel occlusion, increased flow 
through pre-existing anastomoses lead to an increase in vessel wall shear stress, which 
biomechanically activates endothelial cells (Nagel, et al., 1994; Sampath, et al., 1995). 
Subsequent growth processes occur in the collateral tissue, endothelial cells proliferate, 
and monocytes are recruited to the site of active remodelling (Arras, et al., 1998). To 
confirm early-phase cerebral arteriogenesis, the PCA was observed morphologically for 
these specific features of collateral growth 24 hours and 3 days post 3-VO. Histological 
analysis and staining for PCNA 24 hours after 3-VO (Figure 11) showed increased 
levels of proliferation within the endothelial cell layer of the PCA, which remain until 3 
days post 3-VO. Only active cell proliferation can result in an increased PCA diameter 
as observed under maximal vasodilation seven days post 3-VO. 
 
Using an antibody against CD68, monocyte invasion was detected 24h and 3d post 3-
VO, (Figure 11) demonstrating monocyte invasion, which is another major feature of 
arteriogenesis visible in the PCA. This study, for the first time, shows a rapid 
recruitment of monocytes in brain arteriogenesis already at early time points: 24h post 
3-VO, indicating that monocytes have a crucial role in the starting phase of collateral 
growth. Interestingly, previous studies of Buschmann showed that by application of the 
pro-inflammatory colony stimulating factor GM-CSF, cerebral arteriogenesis could be 
stimulated (Buschmann, et al., 2003). GM-CSF stimulated arteriogenesis, due to an 
increase in monocyte recruitment and by prolonging the life span of macrophages 
(Hossmann and Buschmann, 2005). Monocytes exert an essential paracrine function for 
adaptive arteriogenesis, as they enhance the remodelling process of collateral arterial 
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vessels (Hossmann and Buschmann, 2005). The functional relevance of monocytes for 
arteriogenesis was supported by a study from Heil et al., which provides a direct 
positive correlation between collateral artery growth and the number of circulating 
monocytes in the blood stream (Heil, et al., 2002). Finaly, the pre-dominant role of 
monocytes has been shown by two studies using the femoral artery ligation model 
analysing arteriogenesis in the periphery. A study, which aimed at blocking 
transendothelial migration of monocytes via ICAM inhibitory antibodies, demonstrated 
a severe reduction in collateral growth (Arras, et al., 1998). Proof of concept was given 
by the finding that osteopetrotic (op-/op-) mice, which have only minor populations of 
circulating monocytes, only partially recover from femoral arterial occlusion as 
compared to wild type mice (Bergmann, et al., 2006).  
 
In summary, when combining previous findings with results obtained in this study, it 
appears that monocytes are recruited shortly (24h) after activation of endothelial cells 
by high blood flow for contributing to the initiation of cerebral arteriogenesis   
 
4.1.3. Scanning electron microscopy shows distinct endothelial cell phenotypes in 
the PCA 3d post 3-VO 
This study aimed at, for the first time, visualizing the morphology of the endothelial cell 
layer in growing collaterals of the brain after activation by high blood flow. The 
question arises: how structures of diminutive size, such as endothelial cells in a brain 
vessel could be ascertained in detail. In order to develop a novel technique, an 
interdisciplinary cooperation was started with the Institute of Protozoan Biology, Free 
University Berlin (Prof. Hausmann). Techniques, which were approved to image 
animalcule protozoen, would also be able to visualize the endothelial cell layer of a 
brain vessel. However, for preparing brain vessels for scanning electron microscopy, 
several techniques had to be tested for optimal tissue perfusion and staining to provide 
contrast to the image. Furthermore, different tissue glues were checked for feasibility to 
place the length-wise opened PCA on a glass slide. Critical point drying in liquid carbon 
dioxide, and subsequent spotting with ionized gold particles in an argon atmosphere 
succeeded in visualizing endothelial cell layer of the PCA. In conclusion, we managed 
to viszualize much smaller rat brain collaterals, as compared to collaterals of the dog 
heart, which were previously visualized by scanning electron microscopy by Schaper et 
al (Schaper, et al., 1972).  
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Scanning electron microscopy shows clearly, that 3d post 3-VO within the PCA leads to 
a cobblestone-like pattern of the endothelial surface, as compared to sham controls and 
align in the direction of flow. This finding is in line with findings of Schaper et al 
obtained by electron microscopy for early stages of collateral growth in the dog heart, 
who noticed that the formerly smooth endothelial layer becomes ‘‘rocky’’ (Schaper, et 
al., 1976). Schaper argued that endothelial cells loose cell-cell contacts to increase 
vessel permeability for subsequent monocyte invasion. It is reported that deformation of 
endothelial cells under high FSS is a typical feature of early arteriogenesis and is 
augmented by the intracellular edema by activation of ion channels and loss of volume 
control (Voswinckel, et al., 2003). In vitro studies also argued that endothelial cell 
activation can occur by opening of volume-regulated chloride channels or osmotic cell 
swelling via calcium influx (Schwarz, et al., 1992). It is speculated that this 
transformation of endothelial cells stress the cytoskeleton, which is required for gene 
activity typical for vascular remodelling (Ingber, 2002). Furthermore, the “rocky” 
structure, observed in this study by electron microscopy, may also displays a endothelial 
cell activation by flow changes characterized by nuclear protrusions (Figure 12). A 
protrusion of endothelial cells indicates that cells are turning to the mitotic cell cycle 
(McCracken, et al., 1979). This may explain why cells bulking into the lumen stain 
positive for proliferation marker PCNA 3d post 3-VO, as shown in Figure 11C; 
endothelial cells showed more pronounced structures on the cell surface and 
pronounced cell borders, compared to sham control animals, which might indicate a 
general change in gene expression. It may be also speculated that an increase production 
of junctional adhesion molecules after 3-VO is involved in a process of inflammatory 
cell recruitment, facilitating monocyte invasion into the proliferating vessel (Chavakis 
and Orlova, 2006). Furthermore, it is reported that endothelial cells upon elevated fluid 
shear stress produce cilia that protrude from the endothelial surface and float in the 
blood stream to sense blood velocity (Hierck, et al., 2008; Nauli, et al., 2008; Poelmann, 
et al., 2008). Maybe structures observed in this study on brain endothelial cells may 
represent the early formation of such organelles like cilia.  
 
In summary, morphological analysis of early-phase cerebral arteriogenesis in the brain 
shows endothelial cell activation, cell proliferation, and monocyte invasion 24h and 3 
days post 3-VO. Genomic profile analysis of these early events shall help to shed light 
on the molecular patterns involved in the starting processes of arteriogenesis. 
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4.2. Molecular patterns of early-phase cerebral arteriogenesis show related 
patterns between arteriogenesis and angiogenesis 
The molecular mechanisms that initiate the enlargement of collateral vessels are not yet 
fully known. Little is known especially for the cerebral circulation. A prerequisite for an 
elaborate gene expression analysis for arteriogenesis research is a detailed knowledge of 
where to find, and how to selectively isolate collaterals. Morphological studies of early-
phase cerebral arteriogenesis performed in this study, demonstrated many features of 
arteriogenesis in the PCA and identified a particular region of collateral growth in the 
brain. For this study, the ipsilateral posterior cerebral arteries and parts of the posterior 
communicating arteries were selectively extracted as indicated (Figure 13). This study, 
for the first time, provides a comprehensive gene expression analysis at induction of an 
arteriogenic stimulus (enhanced shear stress) by 3-VO, and provides important insights 
into the relationship of molecular expression patterns involved in the onset of collateral 
growth in the rat brain. 
 
Most genes were found deregulated 24 hours post 3-VO in the growing PCA. Global 
gene expression profiles identified 91 genes as upregulated and 73 genes as 
downregulated, as compared to sham-operated groups. A massive amount of data was 
generated that implicates the problems, which would have accompanied non-hypothesis 
driven research. Therefore, molecular patterns were characterized to understand the 
relationship of deregulated genes. 
 
First, Ingenuity network analysis was performed, which identified a superior expression 
network for cardiovascular system development as a molecular background for early-
phase cerebral arteriogenesis. The superior network is characterized by six expression 
patterns (24h post 3-VO), which are functionally related (Figure 14) and include genes, 
which are reported to interact in cellular mobility, proliferation, growth as well as 
inflammatory response (Figure 21).  
Second, Biological function annotation by the DAVID Bioinformatic database looking 
for Gene Ontology overrepresentations, again verifies processes of early phase 
arteriogenesis and identified biological themes for regulation of cell proliferation, cell-
cell signaling, and cell differentiation (Figure 21).  
Discussion                                                                                                                              63 
  
 
 
Figure 21. Scheme demonstrating the molecular expression patterns of early-  
phase cerebral  arteriogenesis    
Early-phase arteriogenesis is characterized by six functional goups, which all share characteristic features 
of cardiovascular system development. Functional annotation indicates that genes deregulated 24h post 3-
VO are related to biological processes such as angiogenesis and inflammation. This implies relevant 
cellular processes such as cell proliferation, migration and de-differentiation, as well as leucocyte 
recruitment.    
 
Patterns such as cellular growth, mobility, and proliferation correlate with the results 
obtained by immunhistochemistry and electron microscopy, showing endothelial cell 
proliferation and swelling. In fact, many genes annotated here to cell proliferation and 
migration, such as kininogen, semaphorin 4f, cell division cycle 2, and neurogenic 
differentiation 1, are published in the context of cancer, angiogenesis, and axon growth. 
Frequently, genes studied in the context of cancer are as well related to tumor 
angiogenesis, which is often a pre-requisite for tumor growth. Therefore, genes, such as 
kininogen, which releases bradykinin, feature a role for angiogenesis. Bradykinin is 
shown to promote angiogenesis by upregulation of bFGF through the B1 receptor or by 
stimulation of VEGF formation via the B2 receptor (Colman, 2006).  
 
Genes involved in neuronal guidance and axon growth such as semaphorin 4f and 
neurogenic differentiation 1 could indicate a contamination by adjacent brain tissue, but 
much more likely those genes are related to angiogenesis and vascular remodelling such 
as arteriogenesis as well. Specialized endothelial cells, resembling axonal growth cones, 
form the tips of growing capillaries (Eichmann, et al., 2005). It is reported that blood 
vessels and nerves are structurally similar complex branched systems. The 
choreographed morphogenesis of both networks suggests that they are directed by 
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genetically programmed mechanisms. Several axon guidance molecules, including 
semaphorins, and ephrins, have also been implicated in vessel growth and angiogenesis 
(Carmeliet, 2005). In particular, semaphoring 3E and its receptor plexin D1 have 
recently been shown to direct endothelial tip cell navigation in sprouting angiogenesis 
(Eichmann, et al., 2005). Therefore genes annotated here to angiogenesis, involved in 
vessel and neuronal network patterning, are likely to be important candidates for 
cardiovascular system development in the context of endothelial cell proliferation and 
migration in early-phase arteriogenesis (Figure 21). 
 
In summary, endothelial cell proliferation and survival is an essential mechanism during 
angiogenesis. Both processes also have a major impact for arteriogenesis, since vascular 
remodelling processes share major features (Carmeliet, 2000). Therefore, further study 
of genes listed in the appendix, which are related to proliferation, may disclose the 
differences of distinct mechanisms between angiogenesis and arteriogenesis.   
 
4.2.1. Molecular patterns of early-phase cerebral arteriogenesis indicate that 
brain arteriogenesis takes place in an inflammatory environment 
Early-phase cerebral arteriogenesis is characterized by a positive regulation of genes 
related to inflammatory response (Table 5). Expression of genes such alpha 2-
macroglobulin, chemokine ligand 14, complement component 1 and 3 and 
lipopolysaccharid binding protein are annotated to processes like leucocyte migration 
and inflammatory response (Appendix). These genes are likely to contributing to early 
processes, which leads to the initiation of collateral formation. To give some examples 
complement component C1q, the first subcomponent of complement system, initiate the 
expression of MCP-1 by human umbilical vein endothelial cells (van den Berg, et al., 
1998). For MCP-1 signaling it was shown to attract monocytes and stimulate 
arteriogenesis in the rabbit periphery (Schirmer, et al., 2004). Second, complement 
component C3a is reported to be a chemoattractant for monocyte-derived dendritic cells 
as shown by Gutzmer et al, (Gutzmer, et al., 2004). Third, lipopolysaccharide binding 
protein is associated with TLR4 signaling, which results in NF-kB mediated 
inflammatory processes. Interestingly, for TLR4 it was shown to induce flow-induced 
outward remodelling (Timmers, et al., 2007). Furthermore, stimulation of collateral 
growth in the rabbit hind limb by LPS, a Toll-like receptor 4 ligand, attracts monocytes 
and markedly stimulated arteriogenesis (Arras, et al., 1998). In fact, this finding 
correlates well with the rapid invasion of monocytes in the perivascular space of the 
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PCA 24h post 3-VO, as observed by CD68 staining (Figure 11). Induction of expression 
of pro-inflammatory genes may be a key event for early arteriogenesis, which again is 
supported by previous findings that pro-inflammatory cytokines like GM-CSF stimulate 
arteriogenesis in the brain (Busch, et al., 2003). This result support the increasing 
evidence, that components of inflammatory responses constitute critically important 
players for initiating arteriogenesis (Arras, et al., 1998; Heil, et al., 2002).  Analysing 
genes, deregulated in early-phase cerebral arteriogenesis related to monocyte migration 
and inflammatory processes, therefore may hold the opportunity for the development of 
a novel therapeutic stimulation of arteriogenesis. 
 
Since expression profiles were obtained from material of isolated vessels in spatial 
distance from the surgical wound (extracranial ligation), detection of gene expression 
caused by post-operative inflammatory response seemed unlikely. Moreover, white 
blood cell count (Figure 16) and serum amyloid alpha levels (comparable to CRP in 
humans) were unaffected. Yet, it has to be considered that any injury and surgery can 
cause a post-operative inflammation, able to lead to an acute phase reaction.  
 
Tzima showed that fluid shear stress triggers the conformational activation of integrins, 
which mediates both the alignment of endothelial cells in laminar shear and the 
activation of NF-kB in response to changes in shear (Tzima, et al., 2002; Tzima, et al., 
2001; Tzima, et al., 2003). Lehoux et al. could show that high flow conditions for 24 
hours subjected to human umbilical vein endothelial cells induce IkappaB alpha 
degradation and NFkappaB p65 phosphorylation, which activates MMP-2 and MMP-9 
(Castier, et al., 2009).  
Furthermore, by initiating complex signal transduction cascades, mechanical forces 
exerted on endothelial cells generate nitric oxide (NO), which leads to vasodilation and 
consequently results in stretching of smooth muscle cells in the vascular wall. Previous 
studies demonstrate that NF-kB is activated within smooth muscle cells by stretch as 
well (Lehoux, et al., 2006).  
Candidate gene promoter analysis of the 53 most strongly deregulated genes identified 
42 genes as having putative NF-kB binding sites and only 5 with SSRE. This result 
shows, that most genes may be regulated by NF-kB activation. In particular, the most 
strongly deregulated protease inhibitors are driven by NF-kB.  
Hence, the overall transcriptional expression patterns indicate the following: shear stress 
exerted by high flow on endothelial cells may be the driving force, which activates 
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arteriogenesis, however, early-phase arteriogenesis 24-post 3-VO is governed by 
inflammatory processes and is associated with activation of NF-kB. NF-kB leads to the 
expression of pro-inflammatory genes and triggers inflammatory processes, such as 
monocyte transmigration into the perivascular space, which could be verified in this 
study. In summary, local inflammatory processes, which directly follow 
mechanotransduction by endothelial cells, still seem to be the most characteristic 
features reflecting the in vivo situation of collateral growth (Figure 21) 
 
4.2.2. Similarities and differences of the molecular patterns of arteriogenesis in 
the periphery and the heart as compared to cerebral arteriogenesis 
Molecular patterns obtained for early-phase cerebral arteriogenesis correlate with a 
pioneer work by Lee et al., who analysed global changes in gene expression of 
collateral growth in the mouse hind limb following femoral artery ligation. Lee et al. 
clustered genes deregulated in peripheral arteriogenesis according to similarity of 
temporal expression patterns. He identified an early induction phase in arteriogenesis 
with many genes deregulated 24h post femoral artery ligation, including genes 
associated with angiogenesis and inflammation. Genes that were upregulated at mid-
phase, defined as those genes starting at day 3, included genes associated with cell cycle 
regulation, cytoskeletal-related genes, and additional inflammation-related genes. 
Therefore, molecular patterns identified herein are in accordance with the early to mid-
phase induction seen by Lee at al. (Lee, et al., 2004).  
Furthermore, Lee at al showed that genes encoding contractile proteins were either 
enhanced or repressed. Downregulation of genes encoding actin components was 
identified for early arteriogenesis in the periphery. For genes negatively regulated in our 
study, biological function annotation identified components of regulatory proteins of 
muscle development and contraction (Table 5B) in the growing PCA, such as 
smoothelin, myosin light chain, and calsequestrin 2. Downregulation of such 
components represent the initial step for smooth muscle cell (SMC) de-differentiation in 
processes of vascular growth. This finding is in line with results obtained by Schaper 
and co-workers (Schaper, 2004), who identified four phases of changes in endothelial 
and SMC phenotypes during collateral growth. Phase one and two are associated with 
early-phase arteriogenesis characterized by SMC de-differentiation. During phase one, 
SMCs turn from a contractile phenotype to an immature, synthetic phenotype, which 
allows proliferation and migration (Schaper, 2004).  
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The second phase is characterized by the controlled digestion of the extra-cellular 
matrix and internal elastic lamina synchronously with a burst of mitotic activity of 
SMCs and endothelial cells (Cai, et al., 2000; Scholz, et al., 2000). Studies performed 
on growing collaterals in the dog heart demonstrate that digestion of extracellular 
matrix is accompanied by the expression of MMPs and their inhibitor TIMP-1 (Scholz, 
et al., 2000). A close relationship between phenotype, migration, and proliferation of 
SMCs and the presence of MMPs (MMP-2 and MMP-9) and TIMP-1 has been reported 
in vitro and in vivo (Hultgardh-Nilsson, et al., 1997; Li, et al., 1996; Pauly, et al., 1994; 
Southgate, et al., 1992). The strong expression of TIMP-1 could be validated in this 
study and was localized by in situ hybridisation in the growing PCA 24h post 3-VO. 
Here enhanced expression of TIMP-1 may play an important role in keeping medial 
structures from disruption by limiting excess proteolysis (Dollery, et al., 1999; Forough, 
et al., 1996). 
 
In this context it is important to mention the difficulty of comparing molecular data 
obtained here in this study with data obtained for arteriogenesis in the periphery or 
heart. Molecular patterns identified here are in accordance with previous studies, 
however, genes identified in detail frequently vary from the study of Lee and Schaper. 
Microarray data found by group of Schaper analysing gene expression of growing 
collateral vessels of the rat hind limb, showed a prominent role of the transient receptor 
potential cation channel, subfamily V, member 4 (Trpv4) (Troidl, et al., 2008). TRPV4 
is activated by a variety of signals, like fluid shear stress and endothelial cell swelling 
(Vriens, et al., 2004). Here upregulation of TRPV4 in the growing PCA could not be 
verified. However, other genes upregulated in early-phase collateral growth of the 
mouse hind limb related to inflammation, such as MCP-1 could be detected as 
deregulated in this study (Appendix, Table 18).  
Other genes expressed in other studies such as TIMP-1 correlate with the findings from 
previous studies. However, temporal expression pattern and localization differ in 
comparison to the expression data obtained in this study for the brain. For instance, in 
the dog heart TIMP-1 could only be detected in the late phase of remodelling 
specifically in the SMCs of collateral vessels. Schaper already suggests that the 
difference of gene expression probably resulted from different species, model, and 
sampling sites (Schaper, 2004). Thus, it is possible that each model of vascular injury or 
growth has its own features of remodelling through different regulating pathways. 
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Furthermore, the studies of Lee, and other studies performed by Schaper, dealt with the 
molecular mechanism of arteriogenesis in the periphery by applying the femoral artery 
occlusion model, which suffered from some major flaws (Boengler, et al., 2003), 
(Boengler, et al., 2003; Boengler, et al., 2003). The femoral artery occlusion model is a 
famous model for measuring blood flow and collateral conductance (performed in this 
study by approximation for bradykinin receptor KO mice). However, for analysing gene 
expression, this model exhibits two major disadvantages.  
First, in the hind limb model, changes in gene expression occur in a region of active 
ischemia caused by femoral artery ligation. In contrast, 3-VO is performed 
extracranially and gene expression is analysed in a vessel far distal to the occlusion. 
Therefore, none of the deregulated genes found in this study are part of the response to 
local ischemia. A second limitation of the hind limb expression study was that the 
proximal portions of the developing collateral vessels are located within the skeletal 
muscle, and the whole adductor muscle was taken for RNA extraction.  
Hence, isolation of collateral vessel tissue is cumbersome, since selective isolation 
(other than microdissection) of the latter often leads to contamination by adjacent 
muscle tissue (peripheral and heart models). In the 3-VO model, selective surgical 
removal and analysis of collateral vascular tissue for gene expression analysis without 
contamination by adjacent tissue could easily be performed (Figure 13). Therefore, the 
3-VO model perfectly allows gene expression studies, rendering it the more suitable 
model for analysing gene expression, as compared to recent studies analysing 
arteriogenesis in the periphery. 
  
4.2.3. Results of molecular analysis of cerebral arteriogenesis differ from results 
data obtained in in vitro studies 
Shear stress is a fundamental determinant of vascular homeostasis regulating vascular 
remodelling, cardiac development, and atherogenesis, but its mechanisms of 
transduction are poorly understood. Mechanosensing pathways are required for the 
earliest-known events in arteriogenesis. Therefore, many in vitro studies aim at 
understanding the fundamental role of shear stress on different types of endothelial cells 
in order to identify target molecules, which initiate remodelling processes and are 
directly associated with mechonsensing. Studies analysing endothelial cell expression 
exposed to high levels of shear stress, show activation of the transcription factor 
Kruppel-like factor 2, which has been published to be an integrator of various 
mechanical and biologic stimuli (Dekker, et al., 2002; Fledderus, et al., 2007). Another 
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outstanding study by Tzima et al. identified a flow-induced mechanosensory complex 
comprised of PECAM-1 (which activates Src), VE-cadherin (which functions as an 
adaptor), and VEGFR2 (which activates PI(3)K) (Tzima, et al., 2005).  
Neither KLF2 nor the compounds of the PECAM-1/VEGF-2 complex were found to be 
deregulated in our study. However, no great scale arteriogenenesis gene expression 
study (Schaper, Lee and others) has so far show deregulation of those components in 
vivo.  
Genomic expression profiles of arteriogenesis generated from in vivo models yield 
complex expression patterns, indicating differential regulation of genes expressed in 
endothelial cells, smooth muscle cells and fibroblasts. In comparison, in vitro studies 
are artificial settings, and studies with endothelial cells under simulated flow conditions 
do not necessarily reflect the in vivo situation. Results change dramatically dependent 
on the stimulation with different compounds, by different types of cultured cells, and 
different flow simulations. This issue is highlighted by reports showing that FSS 
decreases the expression of MCP-1 in cultured endothelium, which is in contrast to the 
in vivo situation. Likewise, shear stress and nitric oxide seem to reduce monocyte 
attachment in vitro, but the exact opposite happens during collateral artery growth 
(Schaper, 2004; Tsao, et al., 1995; Zeiher, et al., 1995).  
 
4.2.4. A novel role for protease inhibitors in early-phase arteriogenesis 
Analysis of the identified expression networks for early-phase cerebral arteriogenesis by 
molecular function annotation showed lowest p-values for the protease inhibitors. The 
most upregulated genes include kininogen (66.4 fold change), TIMP-1 (6.1 fold 
change), A2M (3.2-fold change), and Lipocalin-2 (6.3 fold change). The latter is related 
functionally to TIMP-1, as revealed by network analysis (Figure 14).  
Previously, TIMP-1 and MMPs were reported to be transcriptionally upregulated in a 
model of coronary arteriogenesis in the dog heart (Pipp, et al., 2004). In our study, in 
situ probes for TIMP-1 identified mRNA staining in the intima, media, and adventitia of 
the PCA during arteriogenesis 24h post 3-VO (Figure 18). Hence, TIMP-1 may be 
suggested as a marker for early-phase arteriogenesis in the brain. TIMP-1 controls 
matrix metalloprotease (MMP) activity (e.g. MMP-9 and MMP-2), thereby mediating 
extracellular matrix degradation by proteolysis, an important step during adaptive 
arteriogenesis (Cai, et al., 2000). MMPs are important mediators of remodelling and 
extracellular matrix degradation and regulate smooth muscle cell phenotype, 
proliferation, and migration, maintaining the integrity of the vascular wall (Kenagy, et 
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al., 1997; Kumar and Owens, 2003; Pauly, et al., 1994). However, in contrast to 
upregulation of TIMP-1, we could not detect regulation of MMPs on gene expression 
level in the early phase of arteriogenesis. This might be due to the fact that many MMPs 
are regulated on post-translational level. As shown by network analysis (Ingenuity), 
TIMP-1 is functionally related to Lipocalin 2 (LCN2). LCN2 can be expressed in blood 
vessels upon inflammation, forming a protein complex with MMP-9 and TIMP-1 (Bu, 
et al., 2006). Upon complex formation, degradation of MMP-9 by TIMP-1 is 
significantly inhibited, resulting in prolonged MMP-9 activity. The effect of Lipocalin 2 
on MMP-9 activity was shown to be independent of changes in MMP-9 gene 
transcription (Fernandez, et al., 2005), which gives another possible explanation for 
unchanged MMP expression in early-phase cerebral arteriogenesis (Deindl, et al., 
2001). 
Besides MMP regulation, TIMPs were found to be involved in regulating cell 
proliferation, angiogenesis, and apoptosis (Mannello and Gazzanelli, 2001). Therefore, 
TIMP-1 might also mediate proliferation and protection from apoptosis in vascular cells 
during early phase arteriogenesis. Indeed, promoter analysis identified 9 NF-kB binding 
sites for TIMP-1, which is the highest number obtained for all genes analysed. A further 
role of protease inhibitors independent of their protease-inhibiting enzymatic function is 
therefore likely. Maybe TIMP-1 is regulated directly by inflammation to promote 
activation of vascular cell proliferation. 
So far, A2M has not been reported in context with collateral artery growth. A2M is a 
protease inhibitor negatively regulating a broad range of proteases e.g. trypsin, 
thrombin, and MMPs, removing them by receptor mediated endocytosis (Baker, et al., 
2002). Therefore, A2M might play a role during ECM degradation in arteriogenesis. In 
addition, a transporter function of A2M for growth factors and cytokines has been 
described, modulating cytokine signaling (Borth, 1992). In silico analysis demonstrated 
that A2M can bind the pro-arteriogenic platelet-derived growth factor-BB (PDGF-BB) 
(Crookston, et al., 1993; LaMarre, et al., 1991). A2M can serve as a reservoir for latent 
PDGF-BB, regulating cell migration and proliferation through binding to its receptor. 
Furthermore, A2M binds transforming growth factor-β (TGF-β), vascular endothelial 
growth factor (VEGF), and FGF-2; all of them exhibiting pro-arteriogenic properties 
(Lloyd, et al., 2005; van Royen, et al., 2002). Surprisingly, components of the PDGF-
receptor beta and TGF-β 3 were downregulated, which needs to be further analysed. 
Interestingly, kininogen was the most strongly upregulated gene. RNA in situ 
hybridisation showed that kininogen is highly expressed at 24h post 3-VO selectively in 
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regions of the intima, media, and adventitia of the growing PCA (Figure 18). Kininogen 
as well is a cysteine protease inhibitor, preventing degradation of the extracellular 
vascular matrix by MMPs, thus orchestrating the homeostasis of the vessel wall. In 
kininogen deficient rats, severe aneurysm formation can be observed, pointing towards 
a role for kininogen in vascular remodelling (Kaschina, et al., 2004). However, as well 
as described for TIMP-1, kininogen is a multifunction protein involved in many cellular 
processes.  
In the rat, T-kininogen seems most abundant and is expressed mainly during 
inflammation (Kageyama, et al., 1987), e.g. in the arterial wall after injection of LPS 
into rat aorta (Okamoto, et al., 1998), which correlates with the human LMW kininogen 
splice variant. LPS signals via the transmembrane receptor Toll like receptor 4, which 
activates NF-kB signaling. Promoter analysis performed in this study found 3 putative 
NF-kB binding sites, again highlighting its role in inflammatory processes.  
In general, all kininogens are cleaved by distinct kallikreins to generate bradykinin and 
lys-bradykinin.  Activation of the kinin system is of major importance for vascular 
biology and is involved in regulating vasodilation which counteracts the renin-
angiotensin system (Madeddu, et al., 2007). Furthermore activation of the kinin-system 
by releasing bradykinin has been shown to promote angiogenesis, reduce cardiovascular 
ischemia and protect against stroke in rat and mouse models (Chao, et al., 2006). 
Following the identification of morphological and molecular patterns of early-phase 
cerebral arteriogenesis, this study aimed at identifying novel key players for 
arteriogenesis. Literature screening identified kininogen and bradykinin signaling as a 
high potential target in the context of arteriogenesis research. 
 
4.3. Direct evidence for Bradykinin signaling in arteriogenesis 
Kininogen is the substrate for kallikrein, which liberates bradykinin. Bradykinin 
signaling is mediated by activation of the kinin B1 and kinin B2 receptors, leading to a 
multitude of cellular function, such as cell proliferation, increased endothelial cell 
permeability and leucocyte migration (Pesquero and Bader, 2006). Hence, bradykinin 
signaling exhibit some interesting features similar to those described for collateral 
growth, however, a role for bradykinin in arteriogenesis has not been demonstrated so 
far (section 1.8.).  
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4.3.1. Bradykinin receptor 1 and bradykinin receptor 2 KO mice show reduced 
arteriogenesis  
Results obtained from collateral capacity measurements of bradykinin receptor B1, B2 
and B1/B2 double KO show that all three mice strain exhibit reduced arteriogenesis. 
Hence, this study for the first time gives direct evidence of the functional relevance of 
bradykinin signaling in arteriogenesis. 
Reduced arteriogenesis in bradykinin receptor B1 and B2 KO mice is a considerable 
finding, since both receptors are involved in diverse cellular processes, mediating their 
biological function via different signaling pathways. Actually, both kinin receptors have 
been shown to be involved in angiogenesis; promoting angiogenesis either directly or 
by stimulation of other paracrine substances (Granger, et al., 1994). Results 
demonstrated in this work that arteriogenesis shares genes and pathways similar to those 
reported for angiogenesis (Figure 21). However, for emphasizing a possible role of 
bradykinin signaling in arteriogenesis, the biology of both bradykinin receptors has to 
be discussed in more detail.  
 
Bradykinin receptor 2 is constitutively expressed on various cell types, including 
endothelial cells, smooth muscle cells, nerve fibers, leukocytes, and mast cells (Calixto, 
et al., 2000). Stimulation of the bradykinin receptor 2, mediates activation of the Akt-
eNOS-GSK3Beta pathway, which results in vasodilation and endothelial cell 
proliferation, which may directly induce reparative angiogenesis (Emanueli, et al., 
2004; Yao, et al., 2008). In this work, quantification of the collateral growth displays a 
minor, but significant, reduction of arteriogenesis in B2 receptor KO mice. Hence, 
activation of the Akt-eNOS-GSK3Beta pathway possibly contributes to arteriogenesis, 
since endothelial cell proliferation is an integral part of the outgrowth of preexistent 
collateral arteries. Schaper et al. reported that signaling pathways for arteriogenesis 
involve the MAPKinases, the Rho-pathway, and eNOS dependent pathways, and 
addedd, that the latter two may be worth studying to design stimulators of arteriogenesis 
(Cai and Schaper, 2008). 
It was found that B1 receptor KO mice exhibit a reduced arteriogenic capacity of about 
50%, thus displaying a pronounced phenotype. The reduced capability of collateral 
growth in B1R KO mice corresponds with data obtained by Emanuelli et al., who 
identified significantly reduced angiogenesis and tissue perfusion in a model of hind 
limb occlusion in B1R KO mice (Emanueli, et al., 2002). Stimulation of the B1 receptor 
activates NF-kB along with the production of inflammatory cytokines that promote 
Discussion                                                                                                                              73 
  
 
angiogenesis by a paracrine effects (Krankel and Madeddu, 2009; Medeiros, et al., 
2004). Therefore, the strong phenotype observed in B1 receptor KO mice is most likely 
explained by the leading role of this receptor for inflammatory processes. Lack of B1 
receptor signaling in mice, reduces the production of pro-inflammatory cytokines, such 
as MCP-1 or GM-CSF, for which an important role in promoting arteriogenesis was 
shown. Furthermore, using B1 receptor-deficient mice, several studies showed reduced 
leucocyte transmigration, which depends on this receptor (McLean, et al., 2000; 
Schulze-Topphoff, et al., 2009). As described before (section 1.3. and 4.1.3.) 
transendothelial leucocyte migration, especially that of monocytes and the production of 
inflammatory cytokines are key events in promoting and enhancing collateral growth. 
This might explain the strong reduction in arteriogenesis in B1 receptor KO mice. 
Furthermore, it is reported that leucocytes carry both bradykinin receptors and kinins, 
strongly influencing leucocyte migration (Bertram, et al., 2007). Recent studies 
demonstrate that kinins exert potent chemoattractant effects on human CD133, CD34, 
and murine Lin cKit progenitor cells through a PI3K/Akt/eNOS-mediated mechanism 
(Krankel, et al., 2008). Furthermore, stimulation of leucoctyes with bradykinin 
stimulates the polymorphonuclear leukocyte accumulation and synthesis of cytokines 
(Ahluwalia and Perretti, 1996). 
 
In contrast to constitutive bradykinin receptor 2 expression, there is little bradykinin 
receptor 1 expression in most tissues. Its expression on endothelial cells may be induced 
or enhanced only by cytokines in stressful states, such as inflammation (Marceau, et al., 
1998). Here, recent studies show again the involvement of NF-kB in inducing mouse 
kinin B1 receptor expression (Merino, et al., 2005). 
Analysis of molecular mechanisms of collateral growth shows local inflammatory 
processes during arteriogenesis. Induction of expression of B1 receptor and its critical 
role for inflammation seems likely.  
Interestingly, activation of the constitutively expressed B2 receptor is also capable of 
inducing the expression of the B1 receptor (Phagoo, et al., 1999). Therefore, reduced 
arteriogenesis in B2 receptor KO mice may be a secondary effect and result from a 
delayed bradykinin receptor 1 expression. However, the cross-talk between Bradykinin 
receptors 1 and 2 seems to be much more complicated. 
For instance, bradykinin, which acts basically via bradykinin receptor B2 as well, 
stimulates migration of human monocyte-derived dendritic cells in-vitro, indicating a 
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role of the bradykinin receptor 2 for inflammatory processes as well (Bertram, et al., 
2007). 
 
4.3.2. Bradykinin receptor 1 and 2 double KO mice demonstrate a recovered 
phenotype for arteriogenesis as compared to bradykinin receptor 1 KO 
mice 
Given the role of leucocyte migration, cytokine production, endothelial cell 
permeability, and proliferation for the bradykinin receptor 1 and 2, one would assume 
that B1 receptor and B2 receptor double knock out mice exhibit the pronounced 
phenotype and strongest reduction in arteriogenesis. Surprisingly, arteriogenesis in B1 
and B2 receptor double KO mice was hardly reduced to a larger degree, as compared to 
arteriogenesis in B1 receptor KO mice. In contrast arteriogenesis in the bradykinin 
receptor double KO mice was comparable to the B2 receptor KO mice. Thus, if the B2 
receptor signaling pathway is blocked, in addition to impaired B1 receptor signaling, the 
arteriogenic ability recovers. Hence, it may be speculated that for signaling via the B2 
receptor, two mechanisms are possible, one of which is pro-arteriogenic, the other anti-
arterogenic.  
 
Interestingly, similar results were obtained by Souza et al. in a different scientific 
context (Souza, et al., 2004). Here, the interaction between B1 receptor and B2 receptor 
was investigated in a model of intestinal reperfusion injury. First, Souza et al. analysed 
the role for each receptor alone in rat and later the role of bradykinin signaling for 
reperfusion injury using B1 receptor KO mice. In bradykinin receptor 1 KO mice, 
impaired B1 receptor signaling lead to reduced inflammatory injury after reperfusion, 
suggesting that pro-inflammatory signaling and leucocyte recruitment is decreased. 
Likewise, blocking the B2 receptor by the pharmacological compound Icatibant, results 
in reduced reperfusion injury and inflammation. This again indicated that activation of 
B1 receptor and B2 receptor may directly induce leukocyte migration by kinins, and 
both may also act on leukocytes and/or endothelial cells to release proinflammatory 
mediators. However, if the bradykinin 2 receptor pathway is blocked in addition to 
impaired B1 receptor signaling (similar to the situation in the B1/B2 receptor double 
KO mice), this again results in enhanced reperfusion injury.  
This means that a concomitant B1 and B2 receptor absence and blockage demonstrate a 
recovery of the inflammatory process. Transferring this finding to results obtained for 
arteriogenesis in this study, indicates that recovery of the phenotype of collateral growth 
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in B1 and B2 double KO mice is dependent on the inflammatory process, which has 
been shown to be a driving force for arteriogenesis.  
 
In summary, arteriogenesis in bradykinin receptor 1 and 2 double KO mice is stronger, 
as compared to B1 receptor KO mice, indicating a compensatory effect for 
inflammatory processes. Furthermore, data highlight a yet unknown interaction between 
B1 and B2 receptors and indicate a more complex crosstalk in inflammatory processes.  
 
4.3.3. Transkriptome analysis demonstrate deregulation of kininogens, but not of 
bradykinin receptors in peripheral arteriogenesis 
To assess whether kininogen is expressed at 24h post femoral artery ligation in growing 
collaterals as compared to the brain, adductor muscles were taken from hind limb 
ligated animals for RNA extraction. A 2-fold higher expression of kininogen in the 
adductor muscle of the ligated leg as compared to tissue from the unligated leg was 
detectable. Heterogeneous tissue blurs gene expression data obtained, but the difficult 
anatomy in the hind limb necessitates RNA isolation from adductor muscle. Therefore, 
expression values were expected to be relatively low. This may, on the other hand, 
explain that Lee et al did not find deregulation of kininogen in his genomic approach 
obtained in the mice periphery. 
Molecular analysis of gene expression in growing collaterals did not show different 
expression of the B2 receptor. Expression of the B1 receptor was below threshold. For 
the human B2 receptor, it was shown to be regulated at protein level, and binding of BK 
results in rapid, receptor-mediated ligand internalization accompanied by loss of surface 
receptors (Marceau, et al., 1998), which may explain unchanged expression values. A 
marginal expression of the B1 receptor could be specific for endothelial cells or 
leucocytes which may be hidden in tissue which includes RNA from ECs, SMCs and 
fibroblasts as well.  
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4.4. Summary 
In conclusion, this study presents a functional gene expression analysis as well as a 
comprehensive morphological analysis of collateral pathways in the brain in order to 
gain a more thorough insight into the initial molecular processes during cerebral 
collateral arteriogenesis.  
3-VO leads to redistribution of blood flow via the circle of Willis, inducing 
arteriogenesis in the ACA and PCA. Induction of arteriogenesis is accompanied by 
biomechanical activation of endothelial cells in the PCA, resulting in vascular cell 
proliferation as early as 24 hours post 3-VO with increasing cell proliferation and 
nuclear protrusion in endothelial cells 3 days post 3-VO. Early-phase cerebral 
arteriogenesis is accompanied by macrophage adhesion and invasion into the 
perivascular space of growing collaterals. Following active cell proliferation, PCA 
diameters increase significantly within 7 days post 3-VO.  
In line with these observations, early-phase cerebral arteriogenesis is characterized by 
the expression of genes involved in cell proliferation, cell migration, and cell de-
differentiation. Genes are clustered in six functional related gene expression networks 
involved in cardiovascular system development. Here arteriogenesis is governed by 
genes, which are basically associated to the biological processes of inflammation and 
angiogenesis, notably by expression of protease inhibitors. It is demonstrated that 
protease inhibitors kininogen and TIMP-1 are potential biomarkers for cerebral 
arteriogenesis.  
Enhanced expression of kininogen during early-phase arteriogenesis, exemplifies their 
multifunctional role, not only controlling extracellular matrix degradation, but also 
stimulating collateral growth by specific pathways. Functional relevance of kininogen-
bradykinin signaling for collateral growth was ascertained using the femoral artery 
occlusion model in mouse. Arteriogenesis in the periphery was measured by 
microsphere perfusion. Seven days after femoral artery ligation in B1 receptor knockout 
(KO) mice, B2 receptor KO mice and B1 and B2 receptor double KO mice, 
arteriogenesis was significantly reduced among all bradykinin receptor mutant mice 
strains as compared to wild type animals. Here, bradykinin receptor 1 KO showed 
strongest reduction, and the phenotype of the B1 and B2 double KO mice indicate a 
more complex interaction of both kinin receptors for arteriogenesis, presumably in the 
context of inflammatory processes. However, further studies are needed to examine the 
role of kinins during early-phase cerebral collateral growth. 
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4.5. Study Limitation 
Major foci of this study were to characterize the 3-VO model, analyse the molecular 
features of early-phase cerebral arteriogenesis, and identify kinin signaling as a novel 
candidate for arteriogenesis research. Here, especially for the kinin system, for which 
functional relevance was shown, this study clearly lacks of protein data. 
However, much effort was invovled in performing immunhistochemistry to stain the 
PCA on brain sections for kininogen, B1 receptor 1 and bradykinin. Unfortunately no 
antibody against rat kininogen and bradykinin are available. Antibodies against other 
species were tested for cross-reactivity, but failed in obtaining any result. For staining 
kinin- components in the mouse hind limb, currently ongoing efforts are undertaken 
(Section 4.6).  
 
4.6. Concluding remarks and Outlook 
Myocardial infarction and stroke are the leading causes of mortality in developed 
countries. Ischemic disease affecting lower extremities represents a relevant clinical 
problem as well. Unfortunately, many patients cannot benefit from advances in 
revascularization techniques because of the extension of arterial occlusion. 
Consequently, there is a compelling need for alternative strategies. Collateral circulation 
can significantly influence occurrence and size of cerebral infarction (Liebeskind, 
2004). Therefore, therapeutic stimulation of arteriogenesis might have important clinical 
implications for the development of prophylactic and acute treatments of vascular 
disease (Love, 2003). 
 
In fact, recent studies demonstrate that activating the kinin pathway may protect against 
cardiac dysfunction and stroke (Chao and Chao, 2005; Yao, et al., 2008). Therapeutic 
value in the treatment of ischemic disease by promoting neovascularization was shown 
for the application of kinins (Smith, et al., 2008). This study demonstrates that 
kininogen is a marker of collateral growth in the brain. Furthermore it was shown, that 
kinin signaling is relevant for arteriogenesis. Thus, pharmacological manipulation of 
kinin receptors might open therapeutic options for stimulating arteriogenesis. However, 
further studies are needed to examine the mechanisms of kinin signaling to affect 
arteriogenesis. 
Based on this study, a 3-year postdoctoral fellowship from the Center for Stroke 
Research (CSB), initiated by the Charité Berlin, and founded by the German Ministry of 
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Education and Research (BMBF) was awarded to the author to lay the basis for a 
strategy to induce cerebral arteriogenesis therapeutically as a preventive concept for 
stroke.   
Future projects include, lose-of-function models and gain-of-function models, using the 
3-VO rat brain model. Here, B1 receptor pathway and the B2 receptor pathway are 
pharmacologically inhibited by compound HOE-140 (Jerini AG) and compound H-1960 
(Bachem). Currently, ongoing efforts are undertaken to analyse, in which cerebral 
arteriogenesis is stimulated by application of kinin-compounds. Furthermore, 
cerebrovascular reactivity as a functional parameter of cerebral arteriogenesis shall be 
assessed in rat selectively, overexpressing B1 receptor in endothelial cells. Application 
of bradykinin in animal models of ischemic stroke and subsequent measurement of the 
stroke volume, shall answer the question for a clinical relevance of kinin signaling for 
arteriogenesis. 
Immunhistochemistry of the kinin system in the mouse hind limb post femoral artery 
occlusion, shall give evidence of protein expression in arteriogenesis. However, for 
staining of kinin- components in the mouse hind limb, the collateral region and region 
of interest need to be identified. Finally, collateral capacity following femoral artery 
occlusion in chimeric Bl6/mice after bone marrow transplantation from bradykinin 
receptor KO mice shall be measured. This shall answer the question whether collateral 
growth is regulated by the chemotactic homing of monocytes and other leucocyte sub-
populations to areas of collateral remodelling by kinin signaling. 
However, a major problem has to be considered: the so-called Janus phenomenon of 
arteriogenesis base on the observation that physiological (arteriogenesis) and 
pathophysiological (atherosclerosis) vascular remodelling share molecular features and 
are determined by common genetic programs. For instance, plaque formation in 
atherosclerosis, is accompanied by inflammation, cytokine production, and monocyte 
invasion. Therefore, therapeutic stimulation of arteriogenesis by pro-inflammatory 
cytokines may be inadequate for therapy, since it may have the potential to induce or 
increase atherosclerosis as well. 
Atherogenic and arteriogenic predispositions seem both to be strongly influenced by the 
genetic background. Therefore, genomic studies have to be performed to understand the 
molecular differences contributing to arteriogenesis and atherogenesis. Kinin-mediated 
vascular growth and crosstalk between bradykinin receptor 1 and bradykinin receptor 2, 
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concerning the inflammatory response, might open new avenues for the selective 
stimulation of arteriogenesis. 
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6. Appendix 
Biological function annotation - upregulated genes 
Table 8. GO-Categories Gene List 1 - Biological function annotation  
response to wounding inflammatory response 
AFFY_ID Gene Name AFFY_ID Gene Name 
1370281_at 
fatty acid binding protein 
5, epidermal 1367794_at alpha-2-macroglobulin 
1367794_at alpha-2-macroglobulin 1388485_at 
chemokine (c-x-c motif) 
ligand 14 
1388485_at 
chemokine (c-x-c motif) 
ligand 14 1368000_at complement component 3 
1368000_at 
complement component 
3 1387893_at 
complement component 1, 
s subcomponent 
1387893_at 
complement component 
1, s subcomponent 1387868_at 
lipopolysaccharide binding 
protein 
1387868_at 
lipopolysaccharide 
binding protein 1370215_at 
complement component 1, 
q subcomponent, beta 
polypeptide 
1370215_at 
complement component 
1, q subcomponent, beta 
polypeptide 1367581_a_at secreted phosphoprotein 1 
1367581_a_at 
secreted phosphoprotein 
1 1387050_s_at 
similar to alpha-1 major 
acute phase protein 
prepeptide 
1398258_at apolipoprotein d 1371079_at 
fc receptor, igg, low affinity 
iib 
1387050_s_at 
similar to alpha-1 major 
acute phase protein 
prepeptide 1387088_at galanin 
1371079_at 
fc receptor, igg, low 
affinity iib     
1387088_at galanin     
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Table 9. GO-Categories Gene List 2 - Biological function annotation  
system development cell differentiation 
AFFY_ID Gene Name AFFY_ID Gene Name 
1370281_at 
fatty acid binding protein 
5, epidermal 1368187_at 
glycoprotein 
(transmembrane) nmb 
1386879_at 
lectin, galactose binding, 
soluble 3 1367581_a_at secreted phosphoprotein 1 
1368187_at 
glycoprotein 
(transmembrane) nmb 1368926_at semaphorin 4f 
1370215_at 
complement component 
1, q subcomponent, beta 
polypeptide 1388802_at brain expressed x-linked 1 
1367581_a_at 
secreted phosphoprotein 
1 1367977_at synuclein, alpha 
1368926_at semaphorin 4f 1389123_at 
chemokine (c-c motif) 
ligand 6 
1398258_at apolipoprotein d 1387011_at lipocalin 2 
1388802_at 
brain expressed x-linked 
1 1370042_at stathmin-like 2 
1367977_at synuclein, alpha 1387893_at 
complement component 1, 
s subcomponent 
1370042_at stathmin-like 2 1367712_at 
tissue inhibitor of 
metalloproteinase 1 
1387893_at 
complement component 
1, s subcomponent 1367776_at 
cell division cycle 2 
homolog a (s. pombe) 
1387131_at 
serine (or cysteine) 
peptidase inhibitor, clade 
i, member 1 1369041_at neuroligin 1 
1367712_at 
tissue inhibitor of 
metalloproteinase 1 1369152_at 
protein phosphatase 3, 
regulatory subunit b, alpha 
isoform (calcineurin b, 
type i) 
1371057_at 
gamma-aminobutyric 
acid a receptor, alpha 5 1387088_at galanin 
1389250_at 
lunatic fringe gene 
homolog (drosophila)     
1369041_at neuroligin 1     
1370279_at crystallin, alpha a     
1369152_at 
protein phosphatase 3, 
regulatory subunit b, 
alpha isoform 
(calcineurin b, type i)     
1387088_at galanin     
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Table 10. GO-Categories Gene List 3 - Biological function annotation  
negative regulation of cellular 
process regulation of cell proliferation 
AFFY_ID Gene Name AFFY_ID Gene Name 
1372013_at 
interferon induced 
transmembrane protein 1 
(predicted) 1372013_at 
interferon induced 
transmembrane protein 1 
(predicted) 
1387050_s_at kininogen 1 1387050_s_at kininogen 1 
1368187_at 
glycoprotein 
(transmembrane) nmb 1368187_at 
glycoprotein 
(transmembrane) nmb 
1367712_at 
tissue inhibitor of 
metalloproteinase 1 1367712_at 
tissue inhibitor of 
metalloproteinase 1 
1367581_a_at 
secreted phosphoprotein 
1 1367581_a_at secreted phosphoprotein 1 
1387074_at 
regulator of g-protein 
signaling 2 1388802_at brain expressed x-linked 1 
1367776_at 
cell division cycle 2 
homolog a (s. pombe) 1371079_at 
fc receptor, igg, low affinity 
iib 
1388802_at 
brain expressed x-linked 
1 1387088_at galanin 
1371079_at 
fc receptor, igg, low 
affinity iib     
1367977_at synuclein, alpha     
1387088_at galanin     
 
Table 11. GO-Categories Gene List 4 - Biological function annotation  
response to hormone stimulus 
regulation of multicellular organismal 
process 
AFFY_ID Gene Name AFFY_ID Gene Name 
1367794_at alpha-2-macroglobulin 1387050_s_at kininogen 1 
1369085_s_at 
small nuclear 
ribonucleoprotein n 1368000_at complement component 3 
1370215_at 
complement component 
1, q subcomponent, beta 
polypeptide 1387893_at 
complement component 1, 
s subcomponent 
1367581_a_at 
secreted phosphoprotein 
1 1370215_at 
complement component 1, 
q subcomponent, beta 
polypeptide 
1370362_at 
protein tyrosine 
phosphatase, receptor 
type, n 1367581_a_at secreted phosphoprotein 1 
1387088_at galanin 1371079_at 
fc receptor, igg, low affinity 
iib 
    1387088_at galanin 
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Table 12. GO-Categories Gene List 5 - Biological function annotation  
mononuclear cell proliferation leukocyte mediated immunity 
AFFY_ID Gene Name AFFY_ID Gene Name 
1387050_s_at kininogen 1 1368000_at complement component 3 
1367581_a_at 
secreted phosphoprotein 
1 1387893_at 
complement component 1, 
s subcomponent 
1371079_at 
fc receptor, igg, low 
affinity iib 1370215_at 
complement component 1, 
q subcomponent, beta 
polypeptide 
1387088_at galanin 1371079_at 
fc receptor, igg, low affinity 
iib 
 
Table 13. GO-Categories Gene List 6 - Biological function annotation  
adaptive immune response organ development 
AFFY_ID Gene Name AFFY_ID Gene Name 
1368000_at 
complement component 
3 1370281_at 
fatty acid binding protein 
5, epidermal 
1387893_at 
complement component 
1, s subcomponent 1386879_at 
lectin, galactose binding, 
soluble 3 
1370215_at 
complement component 
1, q subcomponent, beta 
polypeptide 1368187_at 
glycoprotein 
(transmembrane) nmb 
1367581_a_at 
secreted phosphoprotein 
1 1367712_at 
tissue inhibitor of 
metalloproteinase 1 
1371079_at 
fc receptor, igg, low 
affinity iib 1370215_at 
complement component 1, 
q subcomponent, beta 
polypeptide 
   1367581_a_at secreted phosphoprotein 1 
   1371057_at 
gamma-aminobutyric acid 
a receptor, alpha 5 
   1398258_at apolipoprotein d 
   1389250_at 
lunatic fringe gene 
homolog (drosophila) 
   1370279_at crystallin, alpha a 
    1369152_at 
protein phosphatase 3, 
regulatory subunit b, alpha 
isoform (calcineurin b, 
type i) 
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Biological function annotation - downregulated genes 
Table 14. GO-Categories Gene List 7 - Biological function annotation  
muscle development muscle system development 
AFFY_ID Gene Name AFFY_ID Gene Name 
1370937_a_at integrin alpha 7 
1368988_at, 
1387401_at calsequestrin 2 
1387969_at 
chemokine (c-x-c motif) 
ligand 10 1370033_at 
fast myosin alkali light 
chain 
1390827_at 
mad homolog 3 
(drosophila) 1373915_at 
dystrophia myotonica 
kinase, b15 (predicted) 
1372684_at smoothelin 1372684_at smoothelin 
1388876_at, 
1370157_at phospholamban 1388298_at 
myosin, light polypeptide 
9, regulatory (predicted) 
1388298_at 
myosin, light polypeptide 
9, regulatory (predicted)     
 
Table 15. GO-Categories Gene List 8 - Biological function annotation  
circulatory system process embryonic development 
AFFY_ID Gene Name AFFY_ID Gene Name 
1370033_at 
fast myosin alkali light 
chain 1390827_at 
mad homolog 3 
(drosophila) 
1373915_at 
dystrophia myotonica 
kinase, b15 (predicted) 1372299_at 
cyclin-dependent kinase 
inhibitor 1c (p57) 
1369664_at 
arginine vasopressin 
receptor 1a 1389341_at plexin d1 (predicted) 
1388876_at, 
1370157_at phospholamban 1367674_at 
phosphatidylinositol 
transfer protein, beta 
1368154_at 
guanylate cyclase 1, 
soluble, alpha 3 1367859_at 
transforming growth 
factor, beta 3 
    1373032_at 
musculoskeletal, 
embryonic nuclear 
protein 1 
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Table 16. GO-Categories Gene List 9 - Biological function annotation 
regulation of cell proliferation organ development 
AFFY_ID Gene Name AFFY_ID Gene Name 
1386860_at 
milk fat globule-egf 
factor 8 protein 
1368988_at, 
1387401_at calsequestrin 2 
1387969_at 
chemokine (c-x-c motif) 
ligand 10 1370937_a_at integrin alpha 7 
1390827_at 
mad homolog 3 
(drosophila) 1370291_at pdz and lim domain 3 
1372299_at 
cyclin-dependent kinase 
inhibitor 1c (p57) 1387969_at 
chemokine (c-x-c motif) 
ligand 10 
1376066_at 
ras homolog gene 
family, member e 1390827_at 
mad homolog 3 
(drosophila) 
1367859_at 
transforming growth 
factor, beta 3 1372684_at smoothelin 
1372606_at 
cell division cycle 
associated 7 1389341_at plexin d1 (predicted) 
   1367859_at 
transforming growth 
factor, beta 3 
   
1388876_at, 
1370157_at phospholamban 
   1373032_at 
musculoskeletal, 
embryonic nuclear 
protein 1 
    1388298_at 
myosin, light polypeptide 
9, regulatory (predicted) 
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Table 17. GO-Categories Gene List 10 - Biological function annotation 
system development 
positive regulation of cellular 
process 
AFFY_ID Gene Name AFFY_ID Gene Name 
1368988_at, 
1387401_at calsequestrin 2 1386860_at 
milk fat globule-egf factor 
8 protein 
1387969_at 
chemokine (c-x-c motif) 
ligand 10 1387969_at 
chemokine (c-x-c motif) 
ligand 10 
1372299_at 
cyclin-dependent kinase 
inhibitor 1c (p57) 1390827_at 
mad homolog 3 
(drosophila) 
1372684_at smoothelin 1369942_at actinin alpha 4 
1389341_at plexin d1 (predicted) 1376066_at 
ras homolog gene family, 
member e 
1370057_at 
cysteine and glycine-rich 
protein 1 1367859_at 
transforming growth 
factor, beta 3 
1367859_at 
transforming growth 
factor, beta 3 1369664_at 
arginine vasopressin 
receptor 1a 
1388876_at, 
1370157_at phospholamban 1371221_at oxidative stress induced 
1373032_at 
musculoskeletal, 
embryonic nuclear 
protein 1 1387027_a_at 
lectin, galactose binding, 
soluble 9 
1370937_a_at integrin alpha 7     
1370291_at pdz and lim domain 3     
1390827_at 
mad homolog 3 
(drosophila)     
1388298_at 
myosin, light polypeptide 
9, regulatory (predicted)     
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Table 18. Example of target gene validation by qRT-PCR  
24h post 3-VO vs. 24h post sham surgery Fold change  p-value 
Complement Component C1Q beta 2.54 < 0.05 
Lipopolysaccharide binding protein 2.36 < 0.05 
glycoprotein (transmembrane) nmb 3.7 < 0.05 
Phosphatidylserine-specific phospholipase A1 4.17 < 0.05 
MCP-1 - Monocyte chemoattractive molecule 1 2.73 < 0.05 
Excert of target genes validated. Expression is given as fold  
change as compared to sham controls.  
 
Table 19. Vessel diameter mean values 
Vessel Diameter in µm MW 7d Sham SEM MW 7d 3-VO SEM 
PCA ipsi 159 µm 9.0 199 µm 9.9 
PCA contra 143 µm 8.8 189 µm 11 
MCA ipsi 199 µm 6.4 199 µm 7.8 
MCA contra 186 µm 5.4 191 µm 7.8 
ACA ipsi 165 µm 6.7 198 µm 7.8 
ACA contra 158 µm 5.0 188 µm 7.8 
 
Table 20. White blood cell mean values 
White Blood Cell Count MW SEM 
Untreated 9.53 0.36 
24h Sham 10.07 1.58 
24h 3VO 8.64 0.78 
 
Table 21. Collateral conductance mean values 
Collateral Conductance  Mean SEM 
WT 56.17 1.72 
B1 KO 22.41 3.04 
B2 KO 41.53 1.48 
B1/B2 KO 36.74 2.87 
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